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Abstract Animal models aim to replicate the symptoms,
the lesions or the cause(s) of Alzheimer disease. Numerous
mouse transgenic lines have now succeeded in partially
reproducing its lesions: the extracellular deposits of A
peptide and the intracellular accumulation of tau protein.
Mutated human APP transgenes result in the deposition of
A peptide, similar but not identical to the A peptide of
human senile plaque. Amyloid angiopathy is common.
Besides the deposition of A, axon dystrophy and alteration
of dendrites have been observed. All of the mutations cause
an increase in A 42 levels, except for the Arctic mutation,
which alters the A sequence itself. Overexpressing wild-
type APP alone (as in the murine models of human trisomy
21) causes no A deposition in most mouse lines. Doubly
(APP £ mutated PS1) transgenic mice develop the lesions
earlier. Transgenic mice in which BACE1 has been
knocked out or overexpressed have been produced, as well
as lines with altered expression of neprilysin, the main
degrading enzyme of A. The APP transgenic mice have
raised new questions concerning the mechanisms of neuro-
nal loss, the accumulation of A in the cell body of the neu-
rons, inXammation and gliosis, and the dendritic alterations.
They have allowed some insight to be gained into the kinet-
ics of the changes. The connection between the symptoms,
the lesions and the increase in A oligomers has been found
to be diYcult to unravel. NeuroWbrillary tangles are only
found in mouse lines that overexpress mutated tau or
human tau on a murine tau ¡/¡ background. A triply trans-
genic model (mutated APP, PS1 and tau) recapitulates the
alterations seen in AD but its physiological relevance may
be discussed. A number of modulators of A or of tau accu-
mulation have been tested. A transgenic model may be ana-
lyzed at three levels at least (symptoms, lesions, cause of
the disease), and a reading key is proposed to summarize
this analysis.
Introduction
The extracellular accumulation of A peptide in the core of
the senile plaque and the intracellular accumulation of tau
protein as neuroWbrillary tangles and neuropil threads are
today considered the two molecular and morphologic sig-
natures of Alzheimer disease (AD), mandatory for its diag-
nosis [16]. The neuronal loss does not belong to the
diagnostic criteria, but has been also considered an impor-
tant pathological component that should be replicated in a
good model of AD. A peptide, in its native state, is unsta-
ble in water solution (a third of its amino-acids -AA-
sequence is hydrophobic); it forms dimers, trimers, and in
general oligomers. It may Wnally aggregate. The aggregates
of A peptide may exhibit the properties of an amyloid
substance, properties that are attributed to a high content of
-pleated sheet structures: it is stained by Congo red and
thioXavin S, and is Wbrillar at electron microscopy. The
extracellular deposits of A peptide may be diVuse or focal;
some of the focal deposits are amyloid. A peptide
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accumulates not only in the core of the senile plaque but
also in the vessel walls (amyloid angiopathy).
Two successive cleavages are necessary to free the A
peptide from the amyloid precursor protein (APP)—for a
review see [317]. The Wrst one, the so-called -cleavage, at
the extracellular N-terminus of the A peptide, is due to the
beta-site APP-cleaving enzyme (BACE) [42]. It produces a
terminal fragment of APP composed of 99 AA called C99.
The second cleavage, taking place on APP C99, is per-
formed within a lipid membrane by the -secretase complex
(made of presenilin1 (PS1) or presenilin 2 (PS2), Pen 2,
nicastrin and APH 1)—for a review see [340]. The -cleav-
age occurring in the A sequence of APP prevents the pro-
duction of A. Four isoforms of APP are expressed in the
human, of 695, 714, 751, or 770 amino acid residues. APP
751 and 770 contain a protease inhibitor domain, homolo-
gous to the Kunitz type of serine protease inhibitors. In a
few families, AD is transmitted as an autosomal dominant
trait. The mutations that have been found to be responsible
for these cases of familial Alzheimer disease (FAD) are
localized on the APP, PS1 or PS2 genes.
The tau pathology is mainly intracellular: accumulation
of tau may occur in the cell body (neuroWbrillary
tangle = NFT), in the dystrophic axons surrounding the
amyloid core of the plaque, and in the neuropil threads,
which are mainly dendrites. At electron microscopy, tau
protein mainly accumulates as paired helical Wlaments
(PHF).
Before analyzing in some detail the numerous models of
AD that have been proposed in the literature, we would like
to consider, in a general way, the aims that are pursued
when trying to mimic a human disease—and more speciW-
cally a neurodegenerative disease in vivo.
Signs, lesions, cause: the SLC reading key
Animal models aim at replicating the symptoms, the lesions
or the cause of a disease. A “reading key” relating Symp-
toms (S), Lesions (L) and Causes (C) with scores 0–1 is
illustrated in Table 1. In neurology, the signs and symp-
toms (for instance, hemiplegia) are principally linked to the
topography of the lesions (for instance motor cortex), and
are only poorly correlated with their nature (for instance
both cerebral infarct and tumor); in other words, similarity
of clinical signs does not mean similarity in pathogenic
mechanisms. Destroying the cholinergic system with ibote-
nic acid will lead to behavioral symptoms that may resem-
ble those of AD and be amenable to treatments such as
anticholinesterases [226]. It is clear, however, that at the
symptomatic level (S), therapeutic research cannot pretend
to reach an understanding of the pathological mechanisms.
Such a model can aid our understanding of the symptoms
(it can be termed “S1,” i.e., it reproduces signs and symp-
toms), but gives no information on the lesions occurring in
AD (we will qualify it as “L0,” i.e., it gives no information
on the way that lesions appear and interact) or on the cause
of the disease (“C0”): it can therefore be classiWed as
S1L0C0.
At the L level, the model attempts to mimic the lesions:
for instance, amyloid peptide has been injected into the
Table 1 This table illustrates, with examples, the SLC reading key that classiWes the models according to their purpose
The reading key does not intend, in any way, to evaluate the quality of the models, i.e., their adequacy for the purpose of achieving the result. For
instance, whether the cholinergic depletion is excellent or poor, a model that intends to mimic the signs (whatever the actual results), and does not
intend to reproduce the lesions or the cause of the disease, will be type S1L0C0. The value of a model is not necessarily linked to the global score:
a restricted model that would perfectly mimic the mechanisms of the lesion in an area that is spared in the natural disease (S0L1C0) could have a
high scientiWc value
The table also shows that only familial Alzheimer disease (FAD) has been correctly modeled; the cause or causes of sporadic AD are unknown
A reading key for animal models in AD: examples
Models Signs (S) Lesions (L) Causes (C) Final score
Familial Sporadic
Targeted brain lesions 1 0 0 0 S1L0C0
Cholinergic depletion 1  0 0 0 S1L0C0
A injection 1 (depends on site 
of injection)
1 0 0 S1L1C0
Tg APP (mono) 1 1 1 0 S1L1C1 (for FAD)
S1L1C0 (for sporadic AD)
Tg APP (multi) 1 1 0 0 S1L1C0
Tg tau (for expression of tau in the spinal cord) 0 1 0 0 S0L1C0
Tg tau (for expression of tau in the limbic system) 1 1 0 0 S1L1C0
Tg APPxtau 1 1 0 0 S1L1C0Acta Neuropathol (2008) 115:5–38 7
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brains of living mice in an attempt to understand its neuro-
toxicity [262, 290]. The results of such an experiment will
not provide any information on the reason(s) for A accu-
mulation in the extracellular space. The model is of the type
S0L1C0. However, it has also been shown that the A olig-
omers may impede the synaptic functions and be directly
implied in the memory dysfunction [321]; it may therefore
also explain the signs of the disease (S1L1C0). A more sub-
tle example, as discussed later in this article, is the model-
ling of the NFTs of AD by transgenic mice overexpressing
mutated tau. There is no tau mutation in AD, so the model
is clearly not adequate to understand the cause of AD (it is
therefore classiWed as C0). But, however the tangles are
produced, it may be interesting to understand how they
interact with A peptide in transgenic mice which develop
amyloid deposits (L1C0). When the tangles are located in
the limbic system, then the symptoms may mimic those of
AD (S1L1C0); in other mouse lines, the expression of tau
in the motor neurones was responsible for paralyses [247]:
such a model may help to elucidate how the tangles may
cause neuronal dysfunction. It does not aid our understand-
ing of the mechanisms responsible for NFT formation in
AD nor of the clinical signs of dementia (S0L1C0).
Finally, at the C level, the model attempts to reconstruct
the biological mechanisms responsible for the disease,
starting from its cause(s). Transfecting a mutated human
APP experimentally reproduces the cause of familial Alz-
heimer disease, APP mutation. Some lesions similar to
those seen in humans are found in these mouse lines, which
may therefore be classiWed as L1C1. The connection with
the symptoms is far from simple, and it may happen that
these mice do not show the typical clinical signs of AD
(S0L1C1).
The three levels (S, L, and C) are independent: lesioning
the cerebral cortex by an ischemic lesion may, for instance,
mimic the symptoms of dementia; it will have little to do
with both the lesions and the molecular mechanisms of AD:
it is a S1L0C0 model. Introducing a mutated APP gene into
the mouse may mimic familial Alzheimer disease (S1L1C1
for familial AD), but it could well be that the mechanism
has nothing to do with the mechanism of sporadic AD (it is
then classiWed as S1L1C0 or even S0L1C0 as far as spo-
radic AD is concerned). It should be stressed that the cellu-
lar mechanisms which lead to A and tau accumulation,
and eventually to neuronal death, could be replicated in
neurons located outside the cerebral cortex: the pathology
could for instance be fully reproduced in the motor neurone
of the spinal cord. In such a hypothetical example, the
mechanism would be elucidated although the animals
would not exhibit the symptoms and signs of the disease
(S0L1C1), and possibly not even exhibit the lesions that are
presently considered to be the mandatory stigmata of the
disease (S0L0C1)—see Table 1 for examples.
Scope of this review
Which animal models are to be reviewed here? Several pro-
cedures—some of which are listed below—have been
devised in the past to mimic AD in the animal. Destruction
has been used to produce the cortical or subcortical symp-
toms of AD. We will not deal with these models that clearly
belong to the S level. The reproduction of the lesions by
exogenous chemicals has been attempted: NFTs caused by
aluminum have been shown to be actually an accumulation
of neuroWlaments (and not of tau) [185, 225]. Injection of
A peptide may induce some clinical signs [227, 289] or,
under certain conditions, accelerate the pathological pro-
cess in a transgenic mouse—see later and [111]—but it
does not directly reproduce the lesions of the disease [99].
Spontaneous animal diseases, resembling AD, have been
looked for: old monkeys [245] and old bears [66] for
instance, develop plaques and tangles; plaques have been
seen in numerous species, noticeably in old dogs [62, 69],
old cats [68], and in mouse lemurs (Microcebus murinus)
[78]. No model has appeared suYciently practical to be of
common use.
The real breakthrough came from the transgene technol-
ogy. Transgenesis made it possible, probably for the Wrst
time, to reproduce speciWc neurodegenerative lesions. Mice
have overwhelmingly been used and this review will princi-
pally deal with transgenic mice. Recently transgenic rats
have been generated [96] with the aim of improving the
behavioural analysis. Space is insuYcient to deal with
invertebrates models: transgenic drosophilae expressing
beta-amyloid peptides have been devised to screen thera-
peutic targets [67]; the naturally lacking -secretase activity
has been reconstituted in the yeast Saccharomyces cerevi-
siae [92]; the nematode Caenorhabditis elegans has also
been used to elucidate the physiological role of AD molec-
ular protagonists [134]. Flies, yeasts, and worms play the
role of “gene factories,” which are particularly useful for
studying protein interactions and unraveling molecular
pathways. They are, however, too far from the neuropathol-
ogy point of view, centered on the lesions, to be fully cov-
ered in this review.
In vitro models have been used to unravel the physio-
pathological mechanisms involved in AD. This is not the
place to analyze the studies based on the hypothesis of a
direct toxicity of A peptide on the cell. In this paradigm,
the eVect of an experimental manipulation is usually tested
by comparing neuronal death in control and experimental
situations. Cell cultures have also been used to elucidate the
subcellular topography of the secretase activities. BACE is
located in endosomes and also at the cell membrane [142];
Presenilin 1 immunoreactivity is found in the endoplasmic
reticulum, while the gamma-cleavage seems to take place
downstream of the ER (the presenilin “spatial paradox”).8 Acta Neuropathol (2008) 115:5–38
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The production of A42 (but not of A40) appears to take
place in the endoplasmic reticulum/intermediate compart-
ment [63] while A40 is exclusively produced in the trans-
Golgi network [114]. Primary cultures of hippocampal
slices have been extensively used to study the impact of A
oligomers at the electrophysiological level (see later).
This paper is focused on transgenic mice. The literature
has grown rapidly on this topic, and we have been forced,
in many instances, to limit our subject and our analysis of
the literature. The reader is referred to excellent reviews on
the subject [102, 129, 214, 215, 285, 313]. We have delib-
erately not reviewed the eVects of active or passive A
immunotherapy on transgenic (Tg) mice, since this subject
is far too extensive for this review.
SpeciWc problems raised by the pathology 
of transgenic mice
Transgenesis raises speciWc diYculties and questions. The
number of transgenes that have been inserted and their sites
of insertion are uncontrolled. The expression of the gene
may reach high values that trigger cellular defence mecha-
nisms that provide little information on the natural role of
the transgene itself. The topography of the protein expres-
sion and its course during development largely depends on
the promoter. Some defects may be related to anomaly of
development and may be unrelated to the overexpression of
the protein in the adult—a problem which can be solved
through the use of inducible systems of expression (see
later) or by the use of knock-down of gene expression by
siRNA [274]. The genetic background may substantially
modify the pathology [46], and uncontrolled results may be
related to outbred lines. The transgenic animals should, if
necessary, be back-crossed for multiple generations to
obtain inbred lines. The incidence of gender has been men-
tioned in several studies: amyloid deposition has been
found to be more extensive in female APP mice [323].
Pharmacological treatments with intended anti-A eVects
have been found to have diVerent (even opposed) eVects in
male and female transgenic mice, e.g., [240], reinforcing
the contention that gender is a variable to take into account
in the analysis of murine models.
The transgenic models of A accumulation
After the identiWcation of the A peptide, initially in ves-
sels of trisomy 21 patients and then in senile plaques of AD
cases [105, 208, 341], several teams looked for “the” muta-
tion responsible for the rare cases of familial Alzheimer
disease (FAD)—only to realize that not one but numerous
mutations were actually able to cause the disease. Muta-
tions are indeed located not only in the APP gene [52, 106],
from which the A peptide is cleaved, but also in the genes
of presenilin 1 or 2 [4, 259, 280] that are directly involved
in A production from APP.
It is now clear that there is not one but several A pep-
tides, with a C-terminal heterogeneity: some species end at
the AA 40, and others at the AA 42 or even at AA 43, 45,
46 or 48 [248]; the cause of this heterogeneity is still
unknown. Several A species are N-truncated and were
shown to be the main A species in some APP mutations
[173, 275]. All of the mutations that have been tested, when
transfected in cellular models, induce an increase in the
A42/A40 ratio [72], with the noticeable exception of the
Arctic mutation directly involving the A sequence itself
[55]. All mutations induce an overproduction of A except
the mutation V715M, in which, however, the ratio A42/
A40 is increased [6]. Transfecting the APP gene induces
an overproduction of the protein, and APP overproduction
may be suYcient to increase A peptide secretion: both the
 and the  enzymatic activities do not appear to be rate-
limiting. However, as we shall see, APP has generally to be
mutated to produce a quantity of A suYcient to cause vis-
ible changes.
Mutations of the gene of tau proteins are not associated
with AD but with fronto-temporal dementia [284]. It is
therefore logical to consider that AD pathogenesis is related
to a change in APP rather than in tau metabolism. This con-
clusion is formalized as the “cascade hypothesis,” which
states that the accumulation of A peptide is the cause of a
cascade of reactions that lead to tau pathology and neuronal
death [116–119].
Various APP transgenic models
The three isoforms of human APP (hAPP) (695, 751, and
770 amino-acids) have been used as transgenes. The muta-
tions of the APP gene that have been used most often are
labeled by the place where they have been identiWed: Swed-
ish (which is made of two contiguous mutations), London,
and Indiana (K670N & M671L, V717I and V717F, respec-
tively, with the numbering corresponding to the longest
APP isoform). The hAPP gene has been driven by various
promoters—PDGF, Thy-1 or Thy-1.2 (neuron-speciWc),
and hamster PrP (not just neuronal)—which allows its
exclusive or preferential expression in the central nervous
system. A large but certainly incomplete list of the trans-
genic lines pertaining to AD can be found on the Alzforum
website (http://www.alzforum.org/res/com/tra/).
The APP singly transgenic lines
Seventeen amino acids diVer in mouse and human APP;
three of them are located in the A sequence (Arg 5 Gly,
Tyr 10 Phe, His 13 Arg—the Wrst AA is the human one).Acta Neuropathol (2008) 115:5–38 9
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However, increasing the level of mouse APP does not
cause A deposition. Transfection of human APP is neces-
sary [153], and the trisomy16 murine model (where no A
deposition is found) suggests that hAPP has to be mutated
to obtain a reliable and abundant deposition.
Initial attempts Now that numerous mouse lines with A
deposits have been produced, it is interesting to look back
at the Wrst, largely unsuccessful, attempts to develop an AD
model mice [215]. After unconWrmed results of Alzheimer
pathology in transgenics expressing the C-terminal part of
APP [161] or the A peptide under the promoter of APP
[332], several lines were generated with various techniques.
The sequence limited to the A peptide itself, under the
promoter of the light chain of neuroWlament, was neuro-
toxic. A remained intracellular and caused apoptotic cell
death [179]. Since A is partly hydrophobic, its cellular
fate when synthesized outside a cell membrane was proba-
bly not physiological. These pathogenic eVects of A over-
production were probably not directly linked to the
pathogenesis of AD. Several attempts were made to intro-
duce wild-type hAPP into transgenic mice. Several trans-
genic lines were produced with a transgene that comprised
the 100 AA of the C-terminal part of hAPP [160, 228]. A
weak A accumulation was found in the cell body and the
neuropil; C100 was also found to aggregate in vesicular
structures of the cytoplasm [160]. Long-term potentiation
(LTP) was impaired [228], but the extracellular deposits of
A were limited or absent. In the APP-C99 (Tg 13592)
mouse line, the signal sequence and the 99 amino-acids C
terminal fragment (C99) of APP is overexpressed under a
cytomegalovirus enhancer/-actin promoter [97]. The
expression is detected in many tissues, and A deposits are
detected only in the muscle in aged animals. The plasma
concentration of A peptide is increased 17-fold. There are
no deposits in the brain. The mice exhibit hypoactivity and
spatial learning deWcit. This transgenic line indicates that
the increase in plasma A peptide concentration does not
produce amyloid in the brain, and strongly suggests that the
production of A peptide takes place in the brain of FAD
patients rather than at the periphery.
A yeast artiWcial chromosome (YAC) containing wild-
type APP did not induce any visible changes. A YAC
containing the hAPP gene encoding APP harboring the
Swedish mutation, the London mutation or a combination
of the two increased the A42/A40 ratio and decreased
the concentration of -secretase derivatives [184]. A
deposits and neuritic abnormalities were found in the olfac-
tory cortex and olfactory bulb in 14 month-old animals
which expressed a YAC containing APP with the Swedish
mutation, mated to homozygosity [172]. A hAPP 695 trans-
gene with the London mutation driven by the neuron-
speciWc enolase (NSE) was not associated with any
microscopical changes (probably because the levels of A
were not suYcient) [203]. These Wrst attempts indicated
that the A sequence alone was ineYcient; the whole
sequence of APP had to be expressed, and only mutations
were able to cause a signiWcant increase in A 42. The
YAC technology was fruitful, but lesions were observed in
limited amounts and only in old animals. The NSE pro-
moter was not powerful enough to drive A secretion to the
threshold level necessary to cause lesions.
A large number of hAPP singly transgenic mice with
signiWcant changes have since been produced; only the sin-
gly transgenic mouse lines that have been most studied in
the literature are listed below.
The PDAPP transgenic line The transgene of the Wrst
mouse line with signiWcant pathologic accumulation of A
peptide was a cDNA minigene bearing the sequence of
hAPP carrying the Indiana mutation (V717F) with portions
of APP introns 6–8. The presence of introns 7 and 8
allowed the alternative splicing of exons 7 and 8, and the
expression of the 695, 751 and 770 APP isoforms. APP
expression was driven by the PDGF promoter [98]. This
PDAPP transgenic line has been extensively studied. From
the age of six months, the heterozygous mouse develops
visible extracellular deposits of A peptide in the hippo-
campus, and at eight months in the isocortex [98,  146].
Some deposits are amyloid (Congo red and thioXavin S
positive). A peptide is also found in the vessel walls.
The Tg2576 mouse line The Tg2576 mouse line [137]
overexpresses the 695 isoform of hAPP with the Swedish
double mutation (K670N/M671L) under the control of the
hamster prion protein promoter. A diVuse and focal
deposits are found at 9–11 months of age in the heterozy-
gous animal.
The APP23 mouse line In the APP23 mouse line, devel-
oped by Novartis Pharma, the 751 isoform of hAPP with
the double Swedish mutation is expressed under the control
of a mouse Thy-1.2 promoter [292] (the same cDNA under
the control of a human Thy-1 promoter had no pathology).
There is diVuse and congophilic deposition of A peptide
in parenchyma and vessels from six months of age.
Line C3–3 This is also an APP bearing the Swedish dou-
ble mutation, that is overexpressed in this mouse line. The
chimeric mouse/human APP with the Swedish mutation
K670N/M671L contains a humanized A domain. The pro-
moter is the mouse prion promoter. The mice do not
develop plaques until 18 months of age [30, 31].
The Tg CRND8 mouse line The Tg CRND8 mouse bear-
ing both the Swedish double mutation and the Indiana10 Acta Neuropathol (2008) 115:5–38
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mutation (hAPP695 K670N,M671L + V717F), under a
hamster prion promoter, develops plaques at as soon as
three months of age [57]. The high A concentration and
the highly increased A42/A40 ratio explain why this
model is particularly aggressive.
The hAPP H6, J9 and J20 hAPP lines Several Tg lines
expressing, at various levels, wild-type or mutated hAPP
were produced under a platelet-derived growth factor beta
chain (PDGF) promoter. A summary of the most com-
monly used of these Tg animals is given in [222] (p. 4052).
We just mention here the lines that we will consider later:
the J9 and J20 lines, like the Tg CRND8 line, express hAPP
with the Swedish and the Indiana mutation. In these lines,
the human transgene is the isoform 770. The J9 line
(“hAPPlow”) expresses a moderate level of neuronal APP
and A; the level of expression is high in the J20 line [56].
Line H6 also expresses hAPP with the Indiana mutation
under the control of a PDGF promoter [344].
The APPDutch line The E693Q mutation of APP induces
a massive amyloid angiopathy, as described in Dutch
patients. The disease has been replicated by generating a
mouse line expressing hAPP751 with the E693Q mutation
under a murine Thy1.2 promoter. Vascular accumulation of
A with hemorrhages and inXammation have been
observed in these mice [128].
The ARC6 and ARC48 lines The Arctic mutation (E22G)
is located in the A sequence; it stimulates A Wbrillization
without changing the A42/A40 ratio. The transgene is a
minigene containing APP with the Arctic mutation and also
the Swedish and Indiana mutations, under the control of the
PDGF promoter [54].
Data obtained from the comparison of diVerent mouse
lines indicate that the onset and the severity of the amyloid
deposits are directly linked to the level of A42 peptide.
Sturchler–Pierrat et al., in parallel with the APP23, devel-
oped a line in which only a twofold overexpression of
hAPP bearing the Swedish and the Indiana mutations was
obtained. A deposition was seen later than in the APP23
and there was little amyloid formation [292]. In a series of
diVerent mouse lines with a hAPP 751 transgene bearing
the Swedish and the London mutations, the progression of
the pathology appeared to be directly linked to the A42
concentration [257], the level of A(1–40) being higher in
mice that did not show any amyloid deposits. A high level
of A42 is a necessary condition, but it is not suYcient:
Mucke et al. generated diVerent APP transgenic lines under
the same promoter (PDGF); they noticed that the overex-
pression of wild-type hAPP, even if it increased the level of
A42, was insuYcient to cause plaque formation—which
was observed only when the APP transgene carried a patho-
genic mutation known to be responsible for familial AD
[222]. However, the late occurrence of A deposits was
mentioned in two lines (as brieXy and incompletely
described in the literature) in which hAPP, without muta-
tion, was overexpressed under the control of a NSE [130]
or a Thy-1 promoter [128]. Only the overexpression of
APP751, not APP695, was able to induce A deposition in
the Wrst model.
Trisomy 21 models
Chromosome 21, which is present in a triple dose in Down
syndrome, contains the APP gene, which explains why AD
lesions are almost constant at a relatively early age. An
exceptional patient with a partial trisomy 21 that did not
include the APP gene did not develop AD [244]. On the
other hand, microduplication of the APP gene, inducing AD
with prominent amyloid angiopathy, has recently been iden-
tiWed [261]. Models of trisomy 21 (trisomy 16 in the mouse)
have been generated and provide information on the role not
only of the APP gene but also of its contiguous genes in the
pathology. Two segmental trisomy 16 models, Ts65Dn and
Ts1Cje, have contrasted consequences. In the Ts65Dn
mouse [251], a large segment of chromosome 16 including
the APP gene is in three copies, while the segment in tripli-
cate in the Ts1Cje mouse is smaller and does not include the
APP gene nor the gene of the superoxide dismutase 1
(SOD1) [264]. Increased levels of APP mRNA and of the
protein itself have been detected in the Ts65Dn mouse in the
striatum by 6–8 months of age, and in the hippocampus and
parietal cortex by 13–16 months of age. A42 levels have
been found to be increased at six months. At this age, the
basal forebrain cholinergic neurons (BFCN) start degenerat-
ing [141], a degeneration that is related to impaired retro-
grade transport of NGF [64, 265]. Neither total tau nor tau
phosporylated on the serine 199 are elevated in the Ts65Dn
mice [140]. As expected, the level of A42 is normal in the
Ts1Cje mouse line (which has the normal two copies of the
APP gene) and there is no degeneration of the BFCN. How-
ever, and quite unexpectedly, abnormal phosphorylation of
tau has been detected in this mouse line without tangle for-
mation [281]. In the “transchromosomic” 21 model (Tc1),
an almost complete human chromosome 21 has been incor-
porated into the mouse genome [236]. Few data concerning
APP metabolism are presently available.
Early endosomal alterations, the earliest known pathol-
ogy detected in sporadic AD and DS, develop before A is
deposited and as soluble A increases [50]. In the basal
forebrain of Ts65Dn mice, neurons develop enlarged endo-
somes at two months. There is no enlargement of the endo-
somes in the Ts1Cje mice (no APP overexpression) or in
transgenic mice overexpressing APP751 with the SwedishActa Neuropathol (2008) 115:5–38 11
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double mutation alone or in combination with the London
mutation [49]. The cause of endosome enlargement is still
to be fully elucidated.
Presenilin transgenic mice
Mutated human PS1 or PS2, when expressed alone, do not
induce any detectable lesion, although they increase the
level of A peptide [211,  239,  268]. The behavioral
impairment is modest [154, 183]. The mutated PS1 trans-
gene, however, disturbs calcium homeostasis in the endo-
plasmic reticulum [211]. It has furthermore been recently
shown that a mutated human PS1 transgene altered the fast
axonal transport and induced tau hyperphosphorylation
[189].
Doubly transgenic mice
The - and -secretase pathway
APP and BACE (-secretase)
APP plus BACE1
BACE1 cleaves APP at AA 1 of the A peptide but also
at AA 11, producing N-truncated A. BACE1 transgenic
mice (with the promoter of the Ca2+/calmodulin-dependent
protein kinase II gene = CaMKII) have an increased turn-
over of serotonin and exhibit bolder behavior than control
littermates [120]. hAPP mice have been crossed with mice
overexpressing BACE1. The BACE transgene increased
the level of A but also that of the C-terminal fragments of
APP [27]. The coexpression of BACE1 in a transgenic APP
line increased the density of diVuse and focal deposits of
A peptide, but, unexpectedly, dramatically decreased the
severity of amyloid angiopathy. This was considered a con-
sequence of the abundance of N-truncated A species. In
this hypothesis, the N-truncated A peptide accumulates
preferentially in the parenchyma, while the full-length A
peptide may be drained and accumulates in the vessels
[331]. In another study, BACE1 co-expression (murine
Thy1 promoter) with hAPP decreased the level of A and
of APP, but worsened the severity of the neurodegenera-
tion, which is possibly a consequence of the accumulation
of APP C terminal fragments (CTF) [258].
APP minus BACE1
Mice knocked-out for BACE1 are viable and fertile and
do not produce A [199]. They are more anxious and less
exploratory than the controls [120]. Mutation of the
-secretase cleavage site (M671I) on APP also eliminates
the production of human A [223]. Lowering BACE1 lev-
els using lentiviral vectors expressing siRNAs that target
BACE1 reduced amyloid production, and neurodegenera-
tive and behavioral deWcits in APP transgenic mice [282].
Crossing BACE1 KO mice with PDAPP mice [212] or
TG2576 mice [199] prevented the pathology. Loss of
BACE1 function rescued the behavioral alterations [212].
The eVect was even spectacular in PDAPP mice heterozy-
gous for BACE1, although the decrease in A 42 was rela-
tively modest (¡12%) [212]. These results suggest that
inhibition of BACE could be a therapeutic target. Unfortu-
nately, other results indicate that BACE ¡/¡ £ PDAPP
mice have unexpected sensorimotor impairments, spatial
memory deWcits, and display seizures—a phenotype that
could prevent the use of inhibitors of BACE [168].
APP and presenilins (-secretase)
APP plus presenilin
The co-transfection of human mutated (M146L or
M146V) presenilin 1 signiWcantly lowers the age at which
the Wrst plaques are detected [89, 131, 216], most probably
by increasing the quantity of A42 secreted. Wild-type PS1
or PS2 has no eVect [89]. In C3-3 mice crossed with mice
expressing a mutant PS1, the A deposits are visible at
nine months (instead of 18) [30, 31]. The PSAPP line has
been obtained by crossing Tg2576 mice with mice express-
ing human PS1M146L. Amyloid deposits are present at
six months (nine months in the Tg2576 mouse line). In a
APPSLPS1M146L mouse model developed by SanoW-Aventis,
a hAPP751 gene carrying both the Swedish and the London
mutations (K670N/M671L and V717I) under the control of
the Thy-1 promoter is associated with a human mutant gene
of presenilin-1 (PS-1 M146L) under the HMG-CoA reduc-
tase promoter (allowing a preferential cerebral expression).
An intracellular accumulation of A peptide is visible at
two months, and A plaques appear as early as three months
[26, 186]. A similar mouse line with the M233T/L235P
mutations knocked in the PS1 gene (APPSLPS1ki) develops
a very aggressive form of the disease with a prominent
neuronal loss in the CA1 sector [48].
The coexpression of hAPP with the Swedish double
mutation (K670N/M671L) and of PS1 with the L166P
mutation under the control of a neuron-speciWc Thy1 pro-
moter element (APPPS1 mice) dramatically lowers the age
at which the Wrst lesions are visible: cerebral amyloidosis
starts at 6–8 weeks, and the number of microglial cells
increases threefold from one to eight months. Neuronal loss
appears minimal [249].
The 5XFAD model was devised to accelerate A deposi-
tion [231]; these APP/PS1 double transgenic mice coex-
press Wve FAD mutations [APP K670N/M671L (Swedish)
+ I716V (Florida) + V717I (London) and PS1
M146L&L286V]. Intracellular accumulation of A42 is
seen at 1.5 months of age and amyloid deposition begins at
two months.
The deletion of exon 9 in presenilin 1 increases, in man,
the secretion of A peptide and is associated with the
occurrence of large and homogeneous senile plaques that
are only weakly congophilic (the so-called “cotton wool
plaques”). The occurrence of the lesions is accelerated in12 Acta Neuropathol (2008) 115:5–38
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the mouse when a hPS1 gene with exon 9 deleted (line S9)
is coexpressed with a hAPP gene with the APP Swedish
mutation (line C3-3), yielding an APPswe/PS1dE9 line
[100, 191]. The Wrst A deposits are detected at the age of
4–5 months. The E9 deletion of the PS1 gene, rather than
inactivating the gene, induces a gain of function.
APP minus presenilin
The PS1 knockout (KO) mice are not viable. They
have skeletal and CNS deWcits (hemorrhages, deWcient
neurogenesis) which could partly be due to the role of
the -secretase in Notch signaling [279]. Using a loxP/
Cre-recombinase strategy, Dewachter et al. succeeded in
generating a post-natal, neuron-speciWc, PS1 KO mouse.
The absence of presenilin 1 prevented the formation of
A peptide deposits [77]. However, a cognitive deWcit
(object recognition test) was still present in the hAPP
[V717I]  £ PS1 ¡/¡ mice, a deWcit that the authors
attributed to the increase in APP C99 (the product of the
BACE cleavage of APP). The potential toxicity of C99
has been tested in the Tg 13592 line, in which spatial
learning deWcit has been observed in the absence of
brain A deposits.
The -secretase pathway The -secretase cleaves APP in
the A sequence. ADAM10—A Disintegrin And Metallo-
proteinase—is presently the best candidate for the enzyme
responsible for the -secretase activity [170]. The wild-type
human ADAM10 gene, in a mouse line carrying hAPP with
the London mutation, increased the alpha-cleavage of APP,
reduced the concentration of A peptide, and prevented the
formation of A peptide deposits. In contrast, the expres-
sion of an inactive mutant of ADAM10 worsened the
pathology [243].
A degradation Neprilysin
Neprilysin (or neutral endopeptidase 24.11 = NEP or
CD10 or enkephalinase) is thought to be at least partly
responsible for the degradation of A peptide. This metal-
loendopeptidase is inhibited by phosphoramidon and thior-
phan [149]. Transgenic expression of neprilysin improves
the pathology and the behavior in an APP £ PS1 mouse
line with Swedish and Indiana mutations [242]. A lentiviral
vector expressing human neprilysin decreases the density
of plaques by half [205].
Chronic infusion of thiorphan in the rat induces A
deposition [149]. Increased concentration of A peptide is
observed in NEP¡/¡ mice [91, 148]. Amyloid-like depos-
its and signs of neuronal degeneration have been observed
in aged neprilysin-deWcient mice [201]. Loss of NEP func-
tion in APP mice markedly increased hippocampal amyloid
plaque burden, and led to the development of amyloid
angiopathy. Even a 50% reduction in NEP activity was
suYcient to increase amyloid neuropathology [95].
APP £ NEP-KO mice have been shown to develop synaptic
alterations and cognitive deWcits, presumably in relation to
increased levels of A oligomers [138].
Inducible model
The diYculty involved in solubilizing amyloid, whatever
its composition, meant that the question regarding the
course of the disease if the A accumulation is stopped but
the amyloid stays in place remained open. An inducible
model made it possible to study the evolution of the plaques
after the hAPP695 Swedish/Indiana transgene had been
inactivated. It appeared that the amyloid pathology did not
progress, but it did not regress either. The amyloid core
produced the same inXammation and was surrounded by
dystrophic neurites [152].
Conclusions
The alterations observed in these various mouse models are
compatible with a coherent view of APP metabolism: APP
is cleaved by BACE1 and the -secretase complex to pro-
duce A peptide. Higher A levels are observed when
either BACE or the -secretase activity is increased. When
the concentration of A is suYcient, deposits are observed
in the mouse, but only if APP is mutated. Stimulating the -
secretase pathway (ADAM10 transgenic line) or the degra-
dation of A (NEP transgenic line) improves the pathology
and the behavior.
In the next section we consider, from a pathological
point of view, the lesions that are observed in the transgenic
lines. We have distinguished the expected alterations, the
alterations that are present in man and absent in the animal,
and Wnally the lesions that raise new questions or suggest
new points of view.
Pathological consequences of the accumulation 
of A peptide
To simplify the terminology, the ambiguous term “senile
plaque” will be avoided as much as possible. The term
“diVuse” describes the nonamyloid (noncongophilic, non-
Wbrillar), large and irregular A deposits; the term “focal”
describes the small, spherical, intensely immunoreactive
A deposits; and the term “amyloid” is used for the depos-
its that are stained by thioXavin-S or Congo red.
Aspects for which the APP transgenic lines may serve 
as good models of AD
In many ways the APP transgenic mice mimic the amyloid
aspect of AD pathology.Acta Neuropathol (2008) 115:5–38 13
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A production and A deposits While APP overexpres-
sion remains roughly constant during the lives of the APP
transgenic mice, the level of A increases with age. In the
PDAPP mouse line, for instance, A concentrations
increase 17-fold in the hippocampus between the ages of
four and eight months, and by 18 months are over 500-fold
that at four months [158]. From a given age on, the mice,
which produce a large amount of A42, develop visible
deposits Wrst in the hippocampus and isocortex and second-
arily in some subcortical nuclei. Although the topography
of the lesions depends on the transgene promoter, it should
be stressed that the deposition exhibits a laminar pattern
that suggests that A42 is secreted in the terminal Weld of
the neurons, probably just as occurs in humans. In some
lines, this is particularly striking for the perforant path that
links the neurons of layer II of the entorhinal cortex with
the external molecular layer of the dentate gyrus [293]. Sec-
tioning the perforant path prevents the formation of the
amyloid deposits in the molecular layer of the dentate gyrus
[188]. The deposits are Congo red and thioXavin S positive
and are made of amyloid Wbrils 9–11 nm in diameter, as in
AD. The process by which the amyloid Wbrils are formed is
not a mechanical consequence of an increase in APP over-
expression and A peptide concentration. APP may be
expressed at higher levels in regions devoid of plaques than
in areas where they are abundant [158]. It has been shown
that A deposition can be dramatically accelerated by the
injection of amyloid substances from older transgenic mice
or even from human amyloid. Strangely enough, somewhat
similarly to what has been observed in prion diseases, the
Wbrils obtained by simply having the synthetic peptides
precipitated in solution are not eYcient [218, 319].
Amyloid angiopathy Amyloid angiopathy is common in
APP transgenic mice [127]. It was a common belief that A
deposition in the vessel walls of perforating arteries and
subarachnoid vessels was due to the secretion of A pep-
tide by the smooth vascular muscle cells [338]. Tg mice
have demonstrated that this is far from always being true.
In some transgenic lines, amyloid angiopathy appears par-
ticularly prominent—as in the line generated by Van Dorpe
et al. (695 isoform of hAPP—London mutation V717I;
murine Thy1 promoter) [315] and in the line APP23 (iso-
form 751 of APP with Swedish mutation; murine Thy-1.2
promoter) [43]. The role of the A42/A40 ratio is an
important determinant of the distribution of A in vessels
or in parenchyma: the APPDutch mice (E693Q APP751)
develop prominent amyloid angiopathy, associated with an
increased level of A40. However, the APPDutch mice
crossed with PS1G384A Tg mice mainly develop parenchy-
mal deposits, with an increased ratio of A42 to A40
[126]. Since the deposition is seen in transgenic lines in
which A peptide is expressed under a neuronal promoter,
it is highly probable that the peptide produced by the neu-
rons accumulates in the vessel walls [43, 315]. This is com-
patible with the theory put forward by Weller et al. that the
A peptide is drained with interstitial Xuid through the
perivascular space (in a direction opposite to the arterial
blood Xow) [328]. Recently, A peptide was found in the
perivascular space of APP23 mice and also, in small
amounts, in wild-type aged animals. A was colocalized
with ApoE, suggesting that the drainage of A could
involve an interaction with ApoE [301].
Pathology of synapses
Synaptophysin immunoreactivity
Loss of synaptophysin immunoreactivity (IR) has
been considered to be a hallmark of AD pathology and
the best correlate of cognitive deWcit [298], an opinion
that has, however, been under discussion [79]. The
results in the Tg mice have been contradictory. Some
studies reported an absence of change: in the APP23
mouse line, for instance, no loss of synaptophysin IR has
been detected despite robust A deposition [28]. The
loss may be subtle: in the TG2576 APP mouse line, no
loss was initially observed, but rather an increase, corre-
lated with a deWcit in synaptic function [165]; a more
exhaustive stereological and ultrastructural analysis in
the same line found a decrease in the synaptic density of
the external molecular layer of the dentate gyrus, in
close relation to the A deposits [87]. Some studies
report a reproducible loss of synaptophysin IR. The
decrease in density of presynaptic terminals precedes by
several months the extracellular deposition of A pep-
tide in line H6 (see above) [136]. An age-dependent
decrease in synaptophysin IR has been documented in
the PDAPP mouse line [84]. Mucke et al. have generated
several mouse lines expressing either wild-type or
mutated human APP. At the same level of expression of
hAPP, extracellular deposits of A peptide are observed
only when APP is mutated, even when the level of A42
is high. The density of synaptophysin IR is even found
to be decreased in mice expressing wild-type APP with-
out A deposits. It is inversely correlated with the level
of A42, but it is not necessarily associated with a high
plaque load or with a high level of APP expression
[222]. Synaptic alterations can thus be seen in the
absence of extracellular deposit of A peptide. More-
over, an age-related decrease in synaptophysin IR has
been observed in PS1 singly transgenic mice [263]. Pre-
synaptic markers synaptophysin and syntaxin as well
postsynaptic density-95 decreased with age in the
5XFAD model [231].
The density of dendritic spines decreases in the CA1 sec-
tor of PDAPP and of Tg2576 before A deposition [187]. It
has been suggested that the loss of dendritic spines could be14 Acta Neuropathol (2008) 115:5–38
123
related to the toxicity of A oligomers. The density of
spines of rat pyramidal neurones in culture was decreased
after exposure to picomolar levels of soluble oligomers
of A peptide. This eVect is mediated by NMDA-type
glutamate receptor and is reversible [278]. A-derived
oligomers (ADDLs) selectively bind to postsynaptic densi-
ties of presumably excitatory neurons (sparing the inhibi-
tory GABAergic ones) in cultures of highly diVerentiated
hippocampal neurons. This binding is associated with a
decrease in membrane expression of NMDA and EphB2
receptors and with the appearance of abnormally long thin
spines [177].
While the eVect on spines is probably caused by A-sol-
uble oligomers, larger changes observed on dendritic trees
seem to be more directly correlated with Wbrillar amyloid
deposits. In the Tg2576 transgenic line, the dendritic den-
sity is diminished within the boundaries of amyloid-beta
plaques, with the greatest loss (about 80%) in the thioXavin
S positive cores. The processes are abnormally curvy [190].
In the same line, in vivo imaging using multiphoton confo-
cal microscopy reveals spine loss and shaft atrophy of den-
drites near A deposits [304].
In conclusion, the data in the literature indicate a regular
drop in the presynaptic marker synaptophysin in the APP
transgenic mice; this decrease may be seen in the absence
of A deposits (but with high concentrations of A42), and
has been also noticed in PS1 transgenic mice. The Wbrillar
deposits of A peptide, on the other hand, alter the
dendrites.
Long-term potentiation and A oligomers
Long-term potentiation (LTP) is an enhanced synaptic
transmission observed in synapses that have previously
been stimulated. It is studied through electrophysiological
means ex vivo (brain slices) or in vivo. LTP, which can be
considered to be a mechanism that supports learning and
memory functions, was shown to be severely impaired in
old Tg2576 mice [51]. In the PDAPP mouse model, abnor-
mal neurotransmission in hippocampal circuits can be
detected before the formation of extracellular deposits of
A peptides [104]. A peptide oligomers rapidly and sig-
niWcantly block LTP [320]. PS1 mutation alone can also
induce anomalies in synaptic transmission that are similar
to those observed after the application of A42 peptide and
are probably related to a decrease in the number of
synapses [187] rather than to a modulation of their function
[246].
In conclusion, the data in the literature suggest that syn-
aptic alterations could be directly correlated with a high
concentration of A42, the amyloid conformation probably
adding some supplementary detrimental constraints on the
dendrites. They also suggest that electrophysiological alter-
ations may be present in the absence of structural changes
and that A oligomers are responsible for these changes.
Synapses and connections
It has been known for a long time that neurites compris-
ing the corona of the senile plaque contain synapses. The
origin of the axons that contribute to this “innervation” of
the plaque is unknown except in rare circumstances (for
instance, the axons in the superWcial part of the molecular
layer of the dentate gyrus come from the entorhinal cortex;
they probably heavily contribute to the plaques innervation
in that region). It has been possible to track corticocortical
connections with an anterograde tracer in APPxPS1 mice
and to show that some of them came into contact with the
plaque core, while thalamic connections for instance
avoided the plaque by following a curvy trajectory (Fig. 1a,
b) [74, 75]. Entorhinal axons form dystrophic boutons in
Fig. 1a–b Connections of plaques. a The anterograde tracer biotinyl-
ated dextran amine (BDA) was injected into the mediodorsal nucleus of
the thalamus. The prefrontal cortex was examined after Congo red
staining. The anterogradely labeled Wbers are shown in brown (long
arrow). The normal connections are present and avoid the plaque,
whose core is stained by Congo red (small arrow). b BDA was injected
into the posterior cingulate cortex. Labeled Wbers are visible in the
visual cortex (black), which is normally connected with the posterior
cingulate cortex. Several Wbers (arrows) come into contact with the
amyloid deposit (brown; immunolabeled by a polyclonal anti-A42
antibody) and appear dystrophic. Bar =1 0m for a and b. This exper-
iment suggests that only a subset of the cortical connections “inner-
vates” the plaque [75]Acta Neuropathol (2008) 115:5–38 15
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contact with A deposits located in the entorhinal
projection area of the dentate gyrus [241]; aberrant boutons
were found associated with amyloid in ectopic locations
within the hippocampus, the thalamus, white matter tracts,
as well as surrounding vascular amyloid [241]. These data
show the presence of profound changes in neuronal connec-
tions that had been underestimated and probably contribute
to dementia. 
Pathology of neurites and axonopathy The amyloid depos-
its induce massive changes in the neurites that surround
them (the corona of the plaque). They are labeled by antine-
uroWlament and anti-APP antibodies (PDAPP mouse line,
10–12 months of age) [207]. The tau immunoreactivity of
the corona neurites has attracted much attention, since it
may constitute the missing link between A and tau pathol-
ogy. Phosphorylated tau and ubiquitin epitopes generally
appear late on, after 14 months of age in the PDAPP line
[207]. No paired helical Wlaments (PHF) have ever been
identiWed at electron microscopy [207] (with the noticeable
exception of Kurt et al. [176]). The dystrophic neurites in the
Tg2576 mouse are enriched in GSK3, suggesting that this
kinase is principally responsible for tau phosphorylation
[303]. In a APPSwe/L £ PS1 model, most A peptide deposits
are surrounded by a high number of degenerating neurites
containing APP, ubiquitin, and manganese-dependent super-
oxide dismutase. Mitochondrial markers (cytochrome c,
cytochrome oxidase 1, and Bax) are also present in these
degenerating neurites. Phosphorylated tau immunoreactivity
appears late and develops at a slow pace [25].
The accumulation of neuroWlament, APP, tau and ubiq-
uitin epitopes is associated with morphological changes
of the neurites. The amyloid core of the plaques in
PDAPP mice crossed with mice overexpressing yellow
Xuorescent protein (YFP) in a subset of neurons is sur-
rounded by markedly enlarged YFP-labeled axonal and
dendritic varicosities [36]. The geometry of the neurites
in or near the amyloid core is modiWed [190]. The
presence of abnormal axonal varicosities near Wbrillar
deposits has also been observed in vivo by transcranial
two-photon imaging [304] (Tg2576). An alteration of
axonal transport has been considered to be the possible
cause of these changes: spheroids and myelin ovoids,
axonal accumulation of APP, neuroWlament and ubiquitin
are observed in the white matter of the spinal cord [337]
in the APP £ PS1 and APP £ PS1—Ki lines developed
by SanoW-Aventis [26, 336, 337]. Anterograde tracing of
cortical connections has also revealed abnormal boutons
in contact with the amyloid core [75, 241] (Fig. 1a, b).
The tracing of connections by DiI, a lipophilic carbocya-
nine dye, has been used by Capetillo–Zarate et al. [45].
They found, in the APP23 mouse line, a selective vulnera-
bility of commissural neurons.
Pathology of the cholinergic and other neurotransmitter 
systems Cell loss aVecting basal forebrain cholinergic
areas (observed in patients with AD [330]) has not been
reported in transgenic mice ([125]; reviewed in [102])
except in the trisomy 21 model (trisomy 16 in the mouse)
[141,  265]. Dystrophic cholinergic neurites, in contrast,
have been regularly observed in contact with congophilic
plaques [38, 200, 292]. Several studies have demonstrated
decreased cholinergic terminals in APP [103] or APP/PS1
[342] transgenic mice (see however, [81] for mixed
results). The Tg2576 mouse shows a signiWcant elevation in
the density of cholinergic synapses in the frontal and parie-
tal cortices, but in the double transgenic Tg2576 £
PS1M146L the density of cholinergic synapses is signiW-
cantly reduced in the frontal cortex. The size of these syn-
apses is smaller than in wild-type animals in the frontal
cortex and hippocampus [342]. A reorganization of cholin-
ergic innervation (reduction of acetylcholinesterase-posi-
tive Wbers in the subiculum; increased Wber density in CA1
and in the dentate gyrus) has also been mentioned [38].
Minor changes in acetylcholine release were measured by
microdialysis [121]. Decreases in the enzymatic activity of
the cholinergic, serotoninergic and noradrenergic systems
were noticed only in the more aggressive models such as
the APP23 [311]. These data indicate that the changes in
neurotransmission are, as far as presently known, limited in
APP Tg mice, which are therefore poorly adapted to testing
therapeutics aimed at improving neurotransmission in AD.
Alterations that are lacking in the APP transgenic mouse 
models
Despite the many similarities between the pathology of AD
and of its Tg models, the APP Tg mouse is not a perfect
replica of AD. The most striking diVerence is the absence
of NFTs. Even if hyperphosphorylated tau has been
detected with immunohistochemical methods, as we have
seen, PHF has, to our knowledge, never been found. The
link that has been postulated in the cascade hypothesis
between the alteration of APP metabolism and tau accumu-
lation has not been reproduced, and the reason for this fail-
ure is still unknown. On the other hand, the large
predominance of A deposition on all other lesions in the
Tg mice provides a new opportunity to study the eVect of
A accumulation as if in isolation, not mixed with tau
pathology.
Problems and questions
The transgenic animals, by allowing the exploration of
uncharted territories, have revealed new pathogenic possi-
bilities, although many of these cannot yet be proven in the
human. There are, on the other hand, some discrepancies16 Acta Neuropathol (2008) 115:5–38
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between the data obtained in the mice and in man, which
remain unexplained. In this section we discuss the discrep-
ancies and the open questions.
Atrophy The atrophy of the medial part of the temporal
lobe, including the entorhinal cortex, hippocampus and
amygdala, is probably one of the best-established signs of
AD. Atrophy has also been detected in the main APP trans-
genic lines, but with an unexpected time course. Most of
the studies that have evaluated brain atrophy in transgenic
mice have been carried out in the PDAPP model [84, 109,
250, 309, 327]. These investigations reported a reduction in
hippocampal volume and a severe atrophy or agenesis of
Wber tracts (fornix and corpus callosum). The alterations are
already observed in young animals (three months) before
the accumulation of A and show no further deterioration
in older mice [84, 109, 250, 309, 327]. They have to be
considered in parallel with the diYculties met when search-
ing for a signiWcant neuronal loss in Tg animals (see the
next section on “Neuronal loss”). Atrophy in Tg mice may
therefore be the consequence of a developmental defect
[124, 202] that could be ampliWed in strains with speciWc
genetic backgrounds [202]. This observation suggests the
possibility that some functional alterations observed in Tg
mice are related to developmental changes rather than to
the accumulation of A peptide. Alternatively, the atrophy
could be related to early alterations caused by the toxicity
of A oligomers before the formation of plaques.
The comparison, by in vivo MRI, of APP/PS1 Tg mice
(Double Thy1 APP751 SL £ HMG PS1 M146L developed
by SanoW-Aventis [26]) with plaque-free PS1 Tg mice did
not reveal atrophy in young APP/PS1 animals. Hippocam-
pal volumes are not aVected by APP overexpression,
regardless of age. However, an age-related atrophy occurs
in APP/PS1 mice, involving posterior brain regions, includ-
ing the midbrain and the internal capsule, the corpus callo-
sum and the fornix. The pattern of atrophy, which involves
white matter and largely spares the isocortex and hippo-
campus, is diVerent from that reported in AD patients [76].
Neuronal loss Contrarily to the popular belief that neuro-
nal death is the essence of Alzheimer pathology, neuronal
loss is particularly diYcult to assess and opposite views
have been expressed concerning its course and severity in
AD (see for instance [108, 254]). Roughly speaking, two
contrasting opinions have been expressed. For some, the
neurotoxicity of A peptide is directly responsible for the
neuronal death [348]. Numerous cellular models have
indeed shown, in vitro, the toxicity of the peptide (or even
of part of the peptide) and have quantiWed the cell death
that it induces. However, it is not yet clear how these results
obtained outside living tissue can be transposed to the
whole brain. In the human, for instance, large diVuse deposits
are commonly seen in intellectually normal aging persons
and in the absence of overt neuronal death; they may sur-
round normal-looking neurons [73, 80]. On the other hand,
the neuroWbrillary pathology has often been incriminated as
the direct cause of neuronal death. The “ghost tangles” (i.e.,
tangles left in the extracellular space after the death of the
neurons that contained them) are a direct proof of the neu-
ronal death caused by or at least associated with the NFTs
[33]. Finally, other as yet unknown mechanisms have been
incriminated [108].
ConXicting results have also been obtained for the trans-
genic mice, and a paradoxical increase in the number of
neurons has even been noticed in young animals of the
APP23 mouse line [29]. As a general rule, the neuronal loss
has been mild or absent in singly transgenic lines: no sig-
niWcant neuronal loss has been found in the isocortex or
hippocampus of PDAPP mice [146] except in the immedi-
ate vicinity of amyloid focal deposits [307], and in the
Tg2576 mice [145]. Mild neuronal loss was described for
instance in the APP23 mouse line [44] and in the CA3 sec-
tor of PDAPP mice [136]. By contrast, the neuronal loss
was found to be moderate or severe in doubly transgenic
mice (Tg2576 £ PS1-M146L [307]; Swedish and London
mutations  £PS1 (M146L) [271]; Swedish and London
mutations £ knock in PS1 (M146L) [48]; 5£FAD [231]).
In the majority of the lines, the neuronal loss involves the
hippocampus (with a few exceptions—cingulate cortex:
PSAPP mice [307]; layer V of the isocortex [231]). The
cause of the neuronal loss has been discussed: A42 pep-
tide at high concentration [231], amyloid A deposits
[307]; intracellular A [48]. There is, however, some con-
sensus that the possible toxic eVect of A peptide on the
neurons is not direct, since the loss is not correlated with
the amyloid burden, may be absent in regions rich in A
deposits and, in contrast, can be seen at some distance from
them [271].
The nature of the precipitated amyloid peptide The diVerent
isoforms of A peptide are the main [260], and possibly the
only [283], constituent of the core of the senile plaque
observed in the human. These isoforms include full-size A
peptides 42 and 40 as well as N-truncated molecules that
could represent up to 60% of all the A species. The major
truncated variants consist of A peptide starting at AA 2–5
and 8–10 [275]. Post-translational modiWcation leads to
alteration of the A molecule: isomerization, racemization,
pyroglutamyl formation, oxidation, and covalent linkage of
A dimers [175]. As a consequence, the A peptide of the
human senile plaque appears particularly diYcult to solubi-
lize.
A deposits observed in transgenic mice resemble those
depicted in human patients, showing classical immunoreac-
tivity with speciWc anti-A antibodies and also amyloidActa Neuropathol (2008) 115:5–38 17
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characteristics following histochemical stainings (green
Xuorescence with thioXavine-S and Congo red birefrin-
gence under polarized light). The deposits of A peptide in
the APP Tg mice contain A40 and A42 as in the human
[297], but have diVerent physicochemical characteristics.
At variance with what is observed in the human, in the
APP23 Tg mice [175], as in Tg2576 mice [159], the A
peptide is fully soluble in buVers containing SDS. This is
attributed to the lack of the post-translational modiWcations
that are observed in man [175]. Quite intriguing is the weak
aYnity of the transgenic murine amyloid to the Pittsburgh
compound-B (PIB) that is used in the human to visualize
the senile plaques [167]. Changes in aYnity might be
caused by diVerences in the secondary structures of A
peptides deposited in human and mice brain tissues.
The topography of the A deposits The topography of the
A deposits follows, in man, a stereotyped progression that
has been formalized by Thal et al. [302] (isocortex, hippo-
campus, basal ganglia, brainstem, cerebellum). This pro-
gression is not replicated in the Tg mice, where A deposits
often mainly aVect the hippocampus, and where it largely
depends on the promoter that is used.
Intracellular A peptide The abundance, the signiWcance
and even the presence of intraneuronal A peptide (IA) in
man are still under discussion. Since it is diYcult to distin-
guish from lipofuscin, IA has probably been underesti-
mated in human neuropathology. A technical factor altering
the IR of A peptide may have contributed to this underes-
timation: the use of heat enhances the visualisation of IA,
but formic acid impedes it [70, 71, 238]. Formic acid is
commonly used to enhance the IR of extracellular A. The
use of antibodies directed toward the N- and C-termini of
the peptide has demonstrated that the IA is mainly made
up of the 42 isoforms and is N-truncated (see for instance
[113, 325]). IA could therefore be the cleavage product of
- and -secretases. There is some controversy concerning
the abundance of intracellular A peptide: Wegiel et al.
detects it even in glia and at a young age. For them, it is
unrelated to AD pathology, since it is observed in regions
where A deposition does not occur [325]. On the other
hand, for others, intraneuronal A accumulation, which
takes place within the multivesicular bodies [294] (a
specialized form of lysosomes) is an essential factor of the
pathogenesis [18, 113, 178, 294, 334]. It has been seen in
Down syndrome patients before the appearance of senile
plaques [115, 221], and is said to be present in vulnerable
regions before the development of full-blown pathology
[113].
This point of view has been stimulated by the analysis of
Tg mice. Large granules containing A peptide immunore-
activity have indeed been seen within the cortical neurons
of several transgenic lines, such as Tg2576 mice [113,
294], APPSLPS1M146L [186, 335], APPSLPS1 M146LKI [48]
and 3 £ Tg-AD mouse [233, 234]. In the transgenic mod-
els, intraneuronal A accumulation is easy to identify and
much simpler to distinguish from lipofuscin than in man.
The density of intraneuronal A peptide decreases while
the density of extracellular A deposits increases [186, 234,
335], suggesting that the secretion of intracellular A is
responsible for its extracellular accumulation (Fig. 2). The
removal of extracellular A deposits (by immunotherapy)
is shortly followed by the clearance of intraneuronal A,
indicating that there is a dynamic balance between the two
pools [234]. 
In conclusion, the frequency of intracellular A peptide
accumulation and its temporal relationship with the extra-
cellular deposits in transgenic mice raise new questions:
does the intracellular accumulation also constitute a con-
stant stage in the neuropathology of AD? Should the cas-
cade hypothesis be changed accordingly [334]? Is it, in
contrast, due to the overproduction of A peptide, observed
only in a subset of AD (genetic cases)? Is its easy recogni-
tion in Tg animals the mere consequence of the artiWcial
overexpression of APP? If the extracellular A originates
in the intracellular pool, why doesn’t the extracellular pool
only consist of N-truncated species? No other example
Fig. 2 Comparison of extracellular deposition and intracellular accu-
mulation of A peptide in APPxPS1 Tg Mice. Five illustrative mice,
taken at 2, 5, 9, 11, and 15 months of age, were studied. Sections,
25 m in thickness, were immunostained with an anti-A8–17 antibody
(clone 6F/D3; Dako, Glostrup). The extracellular deposits of A pep-
tide are plotted on the left side in green; the intracellular granules of
A peptide are shown in red on the right side. Intracellular A is visi-
ble after just two months, before the appearance of extracellular depos-
its. The density of intracellular A decreases with the increase in the
density of extracellular deposits of A peptide. Scale bar = 1 mm.
ModiWed from [186]
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better illustrates the interplay between AD and its experi-
mental models. The emphasis placed on intracellular A is
clearly a consequence of the scrutiny of the transgenic
mice. On the other hand, its importance in Tg models has
led to a reassessment of its role in the human.
Kinetics of the change Multiphoton confocal microscopy,
which does not induce the lesions caused by the high
energy of the laser beam used in standard confocal micros-
copy, allows the examination of living tissue. This tech-
nique has been applied to living transgenic animals, so that
the cortex can be visualized through a window made in the
skull. Observations made over periods of months have pro-
vided new insight into the kinetics of the A deposits in the
parenchyma and in the vessel walls: focal amyloid deposits
develop rapidly. They could be followed over periods of up
to  Wve months. Most of them remain stable in size and
shape. Only a small population of the deposits grew or
shrunk in Tg2576 mice [59]. The topical application of
anti-A antibodies cleared diVuse and focal deposits over a
3–8-day period [14].
Intracortical injections of adeno-associated virus (AAV)
containing the gene for enhanced GFP in TG2576 allowed
some neurons to be visualized, the processes of which
could be followed over long distances. Around 14% of all
the dystrophic processes in contact with the amyloid core
were dendritic. Neurites did not penetrate the dense amy-
loid cores but curved around them. A severe deWcit in spine
density (¡50%) was noticed within a distance of 20 m
from the plaque edge. A decrease (¡25%) also occurred on
dendrites not associated with plaques. Plaques and den-
drites remained stable over the weeks of observation [286].
In a further study using the same methodology, a small sub-
set of spines (around 5%) was found to appear at one-hour
intervals in the control groups, counterbalanced by a similar
percentage of spines that disappeared. In the Tg2576 mice,
spine elimination increased, resulting in spine loss, espe-
cially in the near vicinity of the plaques [287]. In another
experiment, the dystrophic neurites surrounding the amy-
loid core were visualized by their spontaneous Xuorescence
in the PDAPP/YFP model mentioned earlier, while the
amyloid core was revealed by the in vivo Xuorophore meth-
oxy-X04, which has a high aYnity for amyloid. Dystrophic
neurites appeared stable over a three-day period. Antibod-
ies applied at the surface of the brain partly cleared the A
deposits but also signiWcantly improved the neuritic dystro-
phy within three days [35]. In Tg2576 mice, methoxy-X04
reveals that the Wrst vascular amyloid deposits involve the
leptomeningeal arteries as multifocal deposits of band-like
A. New observations made at weekly intervals showed an
increase in the number of amyloid bands and a widening of
those already present. Over time, the propagation of exist-
ing bands overtook the initiation of new ones [255]. In
conclusion, these lesion kinetics observations indicate that
the amyloid deposits are relatively stable, and that the amy-
loid angiopathy progresses initially by initiating new foci of
deposition and later by increasing their size. The study of
the dystrophic neurites suggests that they are relatively
inert, while a small population of spines is continuously
modiWed by plastic changes. An increase in the number of
disappearing spines that is not balanced by a similar
increase in the number of new spines explains the loss of
spines that is found in the Tg2576 mouse line.
InXammation and gliosis The presence of microglia
within the senile plaque and of astrocytes surrounding
the amyloid core has been known for a long time and is
mentioned in classical textbooks. These glial cells have
been shown to express numerous inXammatory cytokines
(reviewed in [2]). The presence of microglia and of astro-
cytes around the focal A deposits has been abundantly
documented in Tg mice. The Wrst inXammatory changes are
observed quite early, before any visible A deposition.
They are associated with increased BACE activity [123].
However, the cytokines whose expressions are induced by
A peptide, particularly the peptide in its Wbrillar form,
have been discussed and contradictory results have been
published in the literature [20, 209, 217]. In the Tg2576
mouse line, for instance, IL-1 and TNF- -immunoposi-
tive microglia as well as IL6 immunopositive astrocytes
have been found in close contact with amyloid A deposits
[20]; the authors conclude that these changes are similar to
those seen in man. Mehlhorn et al., in the same mouse line,
only found an overexpression of IL-1 in the reactive astro-
cytes that surrounded the amyloid deposits, and concluded
that the local immune response in transgenic Tg2576
mouse brain was diVerent to that observed in brains from
AD patients [217]. The microglial cells present in the
plaque are partly derived from the bone marrow, as demon-
strated by grafting bone marrow from mice expressing
enhanced green Xuorescent protein. Fluorescent microglia
was detected around the amyloid deposits when the graft
had been performed before the onset of pathology; they
were less abundant when the graft was done in an old ani-
mal [204]. The presence of activated microglial cells in
contact with the A deposits has been explained in diVerent
ways: for Wegiel et al. [324, 326], the microglial cell is the
“driving force” responsible for the transformation of non-
Wbrillar A into congophilic amyloid deposits, while for
others it is linked to the inXammation that is associated with
the amyloid core [20,  295]. The eVects of inXammation
have also been discussed and captured through transgenic
technology. It should be noted that several experimental
data have uncovered the positive role of inXammation.
TGF-1 overexpression promoted the clearance of paren-
chymal A by microglial cells but increased amyloidActa Neuropathol (2008) 115:5–38 19
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angiopathy [343]. The level of C3 complement factor was
elevated in these mice. To inhibit C3, soluble complement
receptor-related protein y, a complement inhibitor, was
expressed with hAPP. The amyloid pathology was
increased two- to threefold, suggesting that the activation of
the complement that took place in the Tg mice was useful
[345]. The inhibition of C1q (the recognition component of
the classical complement activation pathway) had an oppo-
site (although less marked) eVect. The absence of its gene
in Tg2576 mice and in APP/PS1 mice did not modify the
amount of A deposition and its amyloid transformation.
However, it was associated with a lower level of glial acti-
vation around the A deposits and improved the loss of
synaptophysin and of MAP2 immunoreactivity. The A
deposits were reduced when double transgenic APPswe/
PS1 delta E9 mice were crossed with mice overexpressing
IL-1  [277]. Injection of lipopolysaccharide into the hip-
pocampus of APP/PS1 mice stimulated recruitment of
microglia and reduced A burden [204]. It is also clear that
passive or active immunotherapy, which both bring anti-A
antibodies into contact with the amyloid deposits, produced
spectacular results in the PDAPP mouse [269] and indi-
cated that inXammation was not necessarily detrimental.
However, the beneWts of inXammation must be con-
trasted with the deleterious eVects observed after the over-
expression of several inXammatory proteins. These data
helped to advocate an anti-inXammatory strategy in AD:
1-anti-chymotrypsin, an acute-phase inXammatory pro-
tein, promoted amyloid pathology when coexpressed with
hAPP in singly Tg mice [224, 230]. Coexpression of Cox2,
an enzyme implicated in inXammation and inhibited by a
class of anti-inXammatory drugs, with APPswe and PS1A246E
did not modify A pathology but induced an elevation in
the number of phosphorylated retinoblastoma (pRb) tumor
suppressor protein and active caspase-3 immunopositive
neurons [346].
In conclusion, the presence of astrocytes and microglia
around the amyloid core of the plaque is seen both in the
human and in the Tg mice. The inXammation is, however,
less severe in the latter [272]. The immunological mecha-
nisms involved, the cytokines that are secreted, and even
the eVect (beneWcial or detrimental) of inXammation
remain the source of much discussion, with contradictory
results published in the literature. The spectacular eVect
of immunotherapy has, however, demonstrated that the
microglia, when correctly stimulated, are able to clear the
extracellular A deposits. This suggests that, on the whole,
triggering an adequately oriented inXammation is a better
strategy than attempting to silence it.
Alteration of neurogenesis in hAPP transgenic mice
Neurogenesis, restricted to the dentate gyrus and the sub-
ventricular zone in the adult, has been found to be enhanced
in Alzheimer disease [157]. Largely divergent results have
been obtained in diVerent mouse lines expressing either
mutated APP alone or mutated APP with mutated PS1. A
two-fold increase in BrdU incorporation in the PDAPP
mice was initially described by Jin et al. [156]. Several
authors found that the proliferation of the neural progeni-
tors was reduced [86, 88, 122], with a parallel reduction in
their survival [122], in connection with the amyloid depos-
its [88] or even before their appearance [86]. Zhang et al.
found the eVect on neurogenesis to be linked to the pres-
ence of a mutant PS1 gene [351]. Finally, the proliferation
was found to be increased by Verret et al., while the sur-
vival at four weeks of the newborn neurons was decreased
in correlation with the A deposits [318]. The eVect could
also depend on the ApoE genotype (see later).
Correlations between pathology and physiological 
alterations
Ideally, mimicking the lesions in a Tg mouse should induce
clinical symptoms that are similar to those seen in man; as
already mentioned, however, the signs depend largely on
the topography of the changes. A L1C1 model could be S0
if the lesions, although a good replica of what is seen in
man, do not occur at the correct place (see the “Signs,
lesions, cause: the SLC reading key” above). We will have
the opportunity to study such situations in tau mice. How-
ever, many attempts have been made to isolate speciWc
signs that could be improved by the treatment and would
allow a therapeutic screening.
Regulation of body weight, body temperature, sleep, increased 
lethality Decreased thermoregulation and altered wake/
sleep patterns have been described in PDAPP mice [139].
APP transgenic mice are occasionally reported to have
reduced body weights and enhanced (premature) lethality
[57, 164, 166, 174, 220]. These alterations depend on the
genetic background and are still poorly understood: neuro-
developmental defects could be one of the factors; acute
events (such as spontaneous epileptic seizures) might also
play a role.
Behavioral changes in Tg mice Anomalous anxiety-related
behaviors are occasionally noted in APP transgenic mice,
taking the form of either neophobia or, in contrast, hypo-
anxiety and reduced inhibition [85,  101,  182,  237]. The
anatomical correlates of these behavioral changes are
unknown.
Neurological disorders Signs of neurological impair-
ments have been described in both single APP and double
APP/PS1 transgenic mice from diVerent lines (i.e., PDAPP,
Tg2576, APP23, TgCRND8, APP/PS1 lines). Motor20 Acta Neuropathol (2008) 115:5–38
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dysfunction and diYculties in coordinating movements are
shown by reduced grip strength and altered behavior on a
beam or an accelerated rotating device (rotarod) [12, 164,
166, 310]. The integrity of sensory functions has not been
fully documented in APP transgenic mice. Enhanced acous-
tic (startle) reXex in TgCRND8 mice may indicate the
abnormal processing of auditory stimuli [213]. Impairments
in visually-guided navigation (swimming to a cued location
in a spatial environment) could reXect compromised visual
abilities [166]. A number of studies indicate that APP trans-
genic mice are hyperactive [12, 85, 132, 166, 182, 237], but
locomotor activity has been shown to be decreased in the
APP23 model that develops severe cerebral amyloid angi-
opathy in addition to parenchymal A plaques [181, 310].
Cognitive dysfunctions Based on the evidence of an
amnesic syndrome and early medial temporal lobe pathol-
ogy in AD patients, behavioral studies in APP transgenic
mice have largely focused on learning abilities for tasks
relying on the integrity of the hippocampus. For reviews,
see [13, 83, 129, 169].
(1) Water maze
This test requires the animal to locate and swim towards
an invisible platform in a water tank. During learning, the
mouse is supposed to build a “cognitive map” of the envi-
ronment, a representation that enables the animal to locate
the platform, regardless of where it enters the pool. Rodents
with damage to the hippocampus are severely impaired.
Almost all APP transgenic models have, to date, been
screened in the water maze task. The majority of these stud-
ies indicate defects in navigation behavior. The transgenic
mice reach the goal later after having traveled a longer dis-
tance; they may have diYculties remembering the location
of the platform when assessed during probe trials. These
types of deWcit, some of which exhibit very early onset [57,
310] have been observed in the PDAPP [53], Tg2576 [137,
329], APP23 [163, 181, 310], TgCRND8 [57], and crossed
APP/PS1 [198] models. It is important to keep in mind,
however, that some reports have failed to demonstrate sig-
niWcant or robust learning and retention deWcits in the water
maze task [132, 164, 166] in both APP and APP/PS1 trans-
genic mice. The reasons for such discrepancies are still
unclear.
(2) Spatial alternation
The rodents have a natural propensity to alternate their
visits from already-experienced locations to new ones. This
behavior, that can either be analyzed spontaneously or con-
ditioned by an explicit reinforced alternation rule, requires
intact working memory abilities. Lesions of the hippocam-
pus but also of the frontal cortex disrupt spatial alternation
[180]. Spontaneous or reinforced spatial alternation has
been extensively studied in the Tg2576 model, with several
reports indicating decreased performances ([51,  65,  131,
137, 182, 237]; see however, [166] for mixed results). The
deWcit is said to be detectable at an early age before overt
A deposition, and to increase with age. The deWcits were
questionable in female APP23 mice [181]. Additional
reports have illustrated reduced spatial alternation in double
APPxPS1 transgenic mice ([131, 132, 333]; see, however,
[197]).
(3) Object recognition
Visual recognition memory is also sensitive to hippo-
campal dysfuntion. Objects are shown to the mouse during
an acquisition phase. Following a variable delay (from min-
utes to several hours), the mouse is placed back in the test
arena, which now contains both familiar (previously
shown) objects and new ones. The natural tendency of
rodents is to explore the new objects (novelty attraction).
Good performance in this test relies on the hippocampus,
the perirhinal and entorhinal cortices, and on their intercon-
nection. Impaired recognition memory has been demon-
strated in both APP [77] and APPxPS1 transgenic mice
[135]. As mentioned earlier, the knocking-out of PS1 did
not rescue the cognitive deWcit in the APP mouse [77].
ConXicting results have been obtained concerning the
object recognition task in the PDAPP mice (deWcit [85]
which is possibly corrected by immunotherapy [82];
absence of deWcit [53]).
(4) Sparing of “procedural memory”
The dichotomy between procedural memory (based on
the acquisition of skills or of a sequence of procedures),
which is relatively spared in AD, and declarative memory,
which is aVected at the initial stage, cannot be directly
applied to animals. Some eVorts have been made to test the
ability to follow procedures in a stereotyped manner and to
contrast it with the ability to build cognitive maps. The
APP Tg mice are still able to apply at least some procedural
strategies [85,  139], especially when given a choice
between multiple strategies to solve problems [24, 219],
thus suggesting selective alterations of diVerent memory
systems in these mice (sparing of procedural memory,
while relational “declarative-like” memories are aVected).
Is extracellular accumulation of A peptide the cause of the 
deWcit? An inverse correlation between cognitive deWcit
and amyloid accumulation has been reported in several
studies involving singly transgenic APP mice (e.g., [53,
84]) and doubly transgenic mice (e.g., [110,  267]). The
good correlation between the areas where A peptide accu-
mulates and the type of cognitive deWcit, and the eYciency
of the immunotherapy in terms of the amyloid load and the
behavioral symptoms also favor the hypothesis of a direct
toxic eVect of amyloid. However, some discrepancies are
poorly compatible with this hypothesis: in some cases, the
deWcit is detectable without A accumulation [131, 310];
sometimes it is observed after the A accumulation hasActa Neuropathol (2008) 115:5–38 21
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taken place [135]; while at other times there is no deWcit
despite a severe amyloid load [23, 24]. Cheng et al. [55],
while working on mice bearing the Arctic mutation that
alters the sequence of the A peptide and makes it more
prone to precipitate in Wbrillar form (without altering the
ratio A42/A40), demonstrated a striking dissociation
between plaque formation and functional deWcits. ARC6
mice had more plaques than J20 mice but essentially no
behavioral deWcits. Furthermore, ARC48 mice had mark-
edly greater plaque loads than J20 mice but comparable or
less severe functional deWcits. This set of results, from
diVerent mouse lines, suggests that it is not the Wbrillar A
peptide sequestred in the plaque that is responsible for the
cognitive deWcit, but rather some other diVusible A spe-
cies [329], or, as suggested more recently, intracellular A
peptide.
Pathogenicity of intracellular A In the previous section
(“Intracellular A peptide”) we mentioned the controversy
over the role of intracellular A peptide in the cascade of
the pathogenetic events leading to neuronal dysfunction.
Intracellular A peptide has also been considered to be
directly responsible for the clinical signs: in the 3£Tg-AD
mouse, synaptic dysfunction is detected before the develop-
ment of A extracellular deposits and of NFTs, but in cor-
relation with intracellular A accumulation [233]. The
deWcit in long-term memory also appeared to be correlated
with the accumulation of intracellular A. Immunotherapy
rescued the deWcit and was associated with the clearance of
intracellular A that reappeared with the cognitive deWcit
when the eVects of the immunotherapy waned [22]. How-
ever, since the density of neurons containing intracellular
A decreases with age, while cognitive deWcits increase,
intracellular A cannot be the unique or even the crucial
factor responsible for the neuronal dysfunction.
Pathogenicity of oligomers Since insoluble Wbrillar A
peptides do not diVuse and are thus unable to play a patho-
genetic role, except by direct contiguity, other A com-
pounds that can be active at some distance from the plaques
have been looked for. As already alluded to, A peptides
easily form dimers, trimers and, in general, oligomers that
pre-exist in protoWbrillar and aggregated A deposits. In
recent years, oligomers have repeatedly been found to play
an important pathogenetic role, particularly in synapses
(see above)—for a review see [322]. In several studies the
presence of oligomers is thought to be necessary to explain
the experimental observations. The total amount of cerebral
A, for instance, was not signiWcantly altered by A immu-
nization, although cognitive dysfunction was improved in a
TgCRND8 murine model of Alzheimer disease, suggesting
that the antibodies acted on soluble A species [155]. Dodart
et al. [82] injected a monoclonal m266 anti-A antibody
into PDAPP mice. The memory deWcits were reversed in
less than 24 h by a single intraperitoneal injection (which
could not modify amyloid burden). The antibodies were
supposed to act directly on the oligomers.
In the Tg2576 mouse line, deWcits in spatial alternation
(Y-maze) were noticed at seven months of age, before A
deposits were seen in the brain, but at a time when the lev-
els of soluble A 40/42 were already elevated [237]. The
memory loss detected at around six months coincided with
the appearance of detergent-insoluble A aggregates, but
the inverse correlation between the aggregation of insoluble
A and memory was lost when age was taken into account.
The authors concluded that the insoluble A was a surro-
gate marker for small assemblies of A peptide that dis-
rupted cognition and occurred as intermediates during the
formation of aggregates [329]. In the same mouse line,
dimeric A peptide was shown to accumulate in lipid rafts
of cell membranes at six months of age, when the Wrst
memory alterations are observed. At that stage, A dimers
are fully soluble in SDS [162]. Lesné et al. looked for an
A species whose accumulation corresponded to the time
course of the decline in spatial reference memory (appear-
ing at six months and remaining stable for 7–8 months
thereafter), again in the Tg2576 mouse line. They found
that A peptide forms stable molecular assemblies that are
preferentially made of trimers. The dodecamers (four tri-
mers) of molecular weight 56 (termed A*56) were the
best correlates of the memory deWcit and the most likely
candidates for the toxic species responsible for the memory
deWcit [192]. A direct test of the hypothesis of the A-olig-
omers was achieved by injecting the conditioned medium
of a cell culture producing large amounts of A peptides
and particularly of oligomers into the lateral ventricle of
rats that had learned an alternation task. This injection
caused a deWcit in the learned task that was “rapid, potent
and transient” [60].
The transgenic models of neuroWbrillary pathology
The Wrst part of this review was centered on A pathol-
ogy. Only dystrophic neurites of the corona of the plaque
contain hyperphosphorylated tau epitopes; paired helical
Wlaments are remarkably absent from these models. The
neuroWbrillary, tau part of the pathology is thus practi-
cally lacking in the Tg mice that we have considered up to
now.
Normal and mutated tau transgene
Tau is a phosphoprotein that belongs to the family of the
microtubule-associated proteins; it binds to tubulin and
facilitates tubule polymerization [61]. It has an axonal22 Acta Neuropathol (2008) 115:5–38
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subcellular localization in the normal adult brain. When
phosphorylated it is detached from tubulin which depoly-
merizes—this depolymerization favors axonal growth and
plasticity. Six isoforms of the protein are known [107],
which diVer in the presence or absence of exons 2, 3, or 10.
An alternative splicing of exon 10 produces either tau with
four repetitive motives (4R tau) or tau with only 3 (3R tau)
[107]. Hyperphosphorylated tau is the main constituent of
NFT of AD, which contains both 3R and 4R tau. The NFTs
of progressive supranuclear palsy and corticobasal degener-
ation are principally or exclusively made of 4R tau [276],
while Pick body contains exclusively or preferentially 3R
tau [39, 40]. The presence of tau immunoreactivity in a
somatodendritic distribution in the absence of true NFT
deWnes the “pretangle” [17]. A somatodendritic distribution
of tau is also found in argyrophilic grain disease. The sub-
cellular distribution of tau (axonal or somatodendritic)
depends on the distribution of its mRNA, not on signals
included in the protein sequence [19]. No change in tau
expression has been detected in AD, but intronic and
exonic mutations of the tau gene are known to be the cause
of frontotemporal dementia linked to chromosome 17
(FTDP-17).
The physiology of tau protein is diVerent in adult mice
and adult humans. Mouse brain contains the 4R tau iso-
forms exclusively, whereas levels of 3R and 4R are
approximately equal in normal adult human brain.
Although mouse and human tau sequences are similar,
there are 14 amino acid diVerences in the N-terminal
region [8].
The normal shortest 3R tau isoform (3R tau without N-
terminal insert) has been introduced into the mouse genome
under the promoter of the murine 3-hydroxy-methyl-gluta-
ryl CoA reductase gene [37]. Tau immunoreactivity was
present in the somatodendritic compartment. Several epi-
topes known to be phosphorylated in AD were also phos-
phorylated, but there were no NFTs. The shortest tau
isoform was also expressed under a murine prion promoter
[147]. Insoluble, hyperphosphorylated tau inclusions were
present in cortical and brainstem neurons but were mostly
abundant in spinal cord neurons. There were no paired heli-
cal Wlaments at electron microscopy. Lines expressing the
longest four-repeat tau isoform under the murine thy-1 pro-
moter (ALZ7 line) [112] developed a peripheral and central
axonopathy [247, 288]. Dilated axons, spheroids, and pre-
tangles were observed without true tangle formation.
Another approach consisted of expressing human geno-
mic tau contained in P1-derived artiWcial chromosomes
(PAC). In line 8c, a PAC containing all 14 exons, exon ¡1,
and more than 7 kb of the 5’ Xanking region, which
includes the tau promoter, was overexpressed in mice. Tau
was distributed in neurites and at synapses, but was absent
from cell bodies. There were no signiWcant pathological
changes, while axonal spheroids and somatodendritic
distributions were observed in mice overexpressing 4R
cDNA [90]. Htau mice were obtained by crossing tau
knock-out mice with 8c mice [8]. Neither tau knock-out
mice nor 8c mice develop any evidence of tau pathology.
Htau mice exclusively express the six normal human tau
isoforms (without murine tau), the level of the 3R isoforms
being signiWcantly higher than that of the 4R isoform [8].
NFTs and extensive cell death were seen in the htau mice,
although they express lower levels of human tau than the c8
mice [8]. This suggests that wild-type murine tau prevents
the aggregation of overexpressed human tau. Cell death in
htau mice does not seem to be directly caused by the NFTs
but appears to be linked to reexpression of proteins
involved in cell-cycle and DNA synthesis [7]. NFTs were
observed at a young age in mouse lines in which the P301L
mutation was introduced [111, 196] or the V337M muta-
tion [296]. Nonapoptotic cell death and tau Wlaments were
observed in transgenic mice with the P301S mutation of tau
protein [3]. The expression of human four-repeat tau with
G272V and P301S mutations under a Thy1.2-promoter
induced neuroWbrillary pathology in the brain with severe
cognitive alteration and no sensorimotor deWcit [270].
In conclusion, PHF and NFT are usually not observed
when any form of wild-type human tau is expressed, except
in the model developed by Andorfer et al. [8] in which
mouse tau gene is knocked-out. In almost all of the models
where cDNA wild-type tau is expressed, the distribution of
tau is somatodendritic; only the construction of DuV et al.
[90] using a minigene preserves a normal subcellular
distribution of tau. Overexpression of mutated tau regularly
produces NFT.
Interaction between tau and A accumulation
The inXuence of A hyperproduction on the neuroWbrillary
pathology was studied in diVerent ways: injection of amy-
loid A42 Wbrils into the brains of P301L mutant tau trans-
genic mice caused a Wvefold increase in the numbers of
NFTs in cell bodies within the amygdala, from where neu-
rons project to the injection sites [111]. In P301L mutant
tau mice crossed with APP Tg2576 transgenic mice, the
amyloid deposits occurred at the same age as in the Tg2576
simple transgenic progenitor, but the neuroWbrillary pathol-
ogy was substantially enhanced in the limbic system and
olfactory cortex, suggesting a synergy between the two
pathologies [195].
On the other hand, reducing endogenous tau ameliorates
or even completely rescues amyloid beta-induced deWcits
(the hAPP Tau ¡/¡ mice had better results on cognitive
test than hAPP Tau +/¡, which, in turn, had better results
than hAPP Tau +/+ mice). The presence of tau protein was
also necessary to produce experimental excitotoxic lesionsActa Neuropathol (2008) 115:5–38 23
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produced by the GABAA receptor antagonist pentylenetet-
razole [256].
The triply transgenic tau model expressing 3R tau (with-
out mutation), APP with the Swedish and the London muta-
tion and PS1 with the M146L mutation, did not develop
true NFTs; however, the human tau transgene and hyper-
phosphorylated tau epitopes were found in the neuritic
component of the plaque [32].
Oddo et al., instead of crossing single transgenic mice,
simultaneously injected a P301L mutant tau transgene and
an APP transgene bearing the Swedish mutation, both
under a Thy 1.2 murine promoter, into single-cell embryos
from mutant homozygous PS1M146V knock-in mice. The
two transgenes appeared to cointegrate at the same locus.
These triple transgenic mice (=3£Tg-AD mice) Wnally bear
a mutated knocked-in PS1 gene, as well as a mutated APP
and a mutated tau gene. At the Wrst stage, A peptide
accumulates intracellularly. A then precipitates in the
extracellular space. Intracellular tau accumulation is Wnally
observed. As in the human, A accumulation is Wrst seen in
the isocortex, while tau pathology Wrst appears in the limbic
system [233]. The electrophysiological alterations (most
noticeably, the deWcit in LTP) are seen before extracellular
accumulation of A peptide at a time when intracellular
accumulation of A is already seen. Moreover, the injec-
tion of antibodies directed against A peptide Wrst cleans
the extracellular deposits before inducing the disappearance
of intracellular accumulation [234]. Normalization of the
electrophysiological alterations is correlated with the disap-
pearance of intracellular A peptide [233]. Increased tau
levels and hyperphosphorylation have no eVect on the onset
and progression of A pathology [232]. However, the cog-
nitive deWcit does not only appear to be linked with A
peptide; soluble tau species are also reduced after active
and passive immunization and could be involved in the
cognitive improvement caused by immunotherapy [235].
What is the physiological relevance of a triple transgenic
mouse to explain sporadic AD or even familial AD (FAD),
which has never been found to be associated with a tau
gene mutation? It is clear that no human disease is pro-
voked by a triple mutation on the PS1, APP and tau genes.
The model can therefore not be considered to describe the
cause of AD, and particularly of sporadic AD (C0). How-
ever, for the Wrst time it integrates all of the lesions that
have been described in the human (L1) in a topography
that, in several ways, resembles the distribution of the
lesions seen in man (S1). This model may therefore be con-
sidered, in our view, to belong to the S1L1C0 type. It is
probably too early to draw from this model the conclusion
that A peptide deposition should precede tau pathology (it
does in the model; this does not warrant that it occurs in this
way in the human). In the same way, the conclusion that
intracellular A is crucial to human pathogenesis because
intracellular A is the best correlate of the electrophysio-
logical signs in this triple transgenic model cannot be
drawn, in our view, without a further and careful analysis of
intracellular A in man.
Persistence of the pathology in conditional KO mice
To analyze the mechanism of progression of the NFT, mice
expressing a repressible human tau variant (rTg4510)
were generated. The responder transgene consisted of a
tetracycline operon-responsive element placed upstream of
a cDNA encoding human tau with four microtubule binding
repeats (4R tau) and the P301L mutation. Doxycycline,
when introduced into the food and water, suppresses trans-
gene expression. Before doxycycline administration, the
mice developed progressive age-related NFTs, neuronal
loss, and behavioral impairments; when the expression of
human tau was repressed, the cognitive deWcit recovered
and the neuronal loss remained stable but the number of
NFTs continued to increase. This observation suggested
that, not unlike what was observed in A pathology, the
toxic eVect of tau was not linked to the visible lesions (i.e.,
NFTs) but to another tau species, the production of which
was prevented by the repression of the tau gene [266].
These tau assemblies appear to be, just as in A pathology,
multimers [21]. The toxic tau multimers of 140 and
170 kDa probably contain full-length tau [21]. The progres-
sion of NFT despite the silencing of the mutated tau gene
could indicate that NFTs, once present in the human brain,
will progress even if a putative treatment is targeted at their
cause.
Modulation of APP transgene
The eVects of overexpressing or knocking out various
known or supposed modulators of A secretion have been
studied in the literature.
Modulation of A secretion by APOE
Apolipoprotein E (ApoE) is a protein involved in choles-
terol transport. Its main receptor, the low-density lipopro-
tein receptor-related protein (LRP), is widely expressed in
the central nervous system. Moreover, ApoE [229,  305,
306] and LRP [10] appear to be bound with A in a large
subset of senile plaques. Much was expected of studies
using Tg mice to elucidate the role of ApoE; the risk of
developing AD is indeed increased in people bearing the
epsilon 4 allele [291]. Actually, the expression of the vari-
ous isoforms of human ApoE in Tg mice and the knock-out
of the ApoE gene in the mouse brought conXicting results
and somehow increased the complexity of the problem.24 Acta Neuropathol (2008) 115:5–38
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EVects on A deposition
A comparative study of the time courses of A42, A40,
and ApoE deposition in relation to astrogliosis in Tg2576
suggested that A42 preceded ApoE in the plaque, fol-
lowed by A40, which occupied the center of the deposit in
later stages. Moreover, the presence of ApoE was corre-
lated with the astrogliosis [297]. The A deposits were
compared in heterozygous V717F APP Tg mice
(APPV717F+/¡) with graded expression of the mouse ApoE
gene. The mice carried no (ApoE ¡/¡), one (ApoE +/¡) or
two (ApoE +/+) alleles. Amyloid deposits as well as A
immunoreactivity were lacking in the cortex in the absence
of ApoE expression in animals aged 22 months. A deposi-
tion was observed—although at a lower level than in the
ApoE +/+ mice—when only one allele (ApoE +/¡) was
present. ApoE immunoreactivity was found in all of the thi-
oXavin S positive amyloid cores in the Tg mice with one or
two ApoE alleles [15]. In a later study with homozygous
V717F APP Tg mice (APPV717F+/+) on an ApoE null back-
ground, it was found that the cortical and dentate gyrus
deposition of A was dramatically reduced, but that the
densities of the CA1 and CA3 diVuse deposits were
increased even when there was no thioXavin S positive
deposits [144]. The overexpression of ApoE4 in a hAPP
mouse, knocked out for ApoE, increases the number of
focal, amyloid deposits tenfold in comparison with the
ApoE3 mice [133]. Since the dystrophic neurites that are
found in the coronae of the plaques are only observed when
the deposit is focal with amyloid, it is no wonder that no
“neuritic plaques” are found in the ApoE ¡/¡ mice. The
role of ApoE itself in the neuritic degeneration is discussed
[133]. In heterozygous V717F APP Tg mice, A deposition
was compared in mice expressing no ApoE, murine ApoE,
or the various human ApoE isoforms (ApoE2, E3, and E4).
As previously shown, ApoE was not necessary but it
enhanced the formation of Wbrillar A. Murine ApoE was
the most eYcient, then human ApoE4, E3 and E2. In other
words, as in man, ApoE2 and ApoE3 delayed the formation
of amyloid deposits when compared to murine ApoE and
human ApoE4 [94]. In Tg mice bearing one allele of the
Swedish mutation (APP sw+/¡), the expression of the human
ApoE4 (ApoE4+/¡) (under the human transferrin pro-
moter) accelerated A deposition and amyloid formation
[47]. However, in another study, the overexpression of
human ApoE4 under a murine prion protein promoter
(responsible for neuronal and glial expression) did not
modify the amount and progression of A deposition in Tg
mice expressing human APPswe or APPswe and PS1 with the
deletion of exon 9 [193]. Van Dooren et al. compared the
eVects of expressing human ApoE4 in neurons (thy1 gene
promoter) or in glia (GFAP gene promoter) in hAPP V717I
singly transgenic and APP-V717I £ PS1-A246E doubly
transgenic mice (thy1 gene promoter for both transgenes).
All of the mice were female and hemizygous for the trans-
gene. The thy1 gene promoter construct is practically unex-
pressed in the thalamus. The presence of the human ApoE4
allele had a diVerential eVect on cortex and thalamus, which
also depended on its production cells (neuronal or glial): in
the cortex, neuronal ApoE4 increased the number of diVuse
deposits of A, while in the thalamus, the density of both
diVuse and focal deposits increased with neuronal and with
glial ApoE. Neuronal ApoE promoted cortical amyloid
angiopathy, while both neuronal and glial ApoE had a
similar eVect on the thalamus. ApoE did not inXuence APP
processing and was not associated with tau hyperphosph-
orylation (probably because the ApoE transgene was
hemizygous) [314]. Since APP was not produced in the
thalamus in these constructs, the accumulation of diVuse or
focal A in this topography was related to its migration.
EVects on tau
ApoE could have more widespread eVects than suspected.
Neuronal but not glial expression of ApoE4 resulted in
hyperphosphorylation of protein tau and caused prominent
axonopathy by disrupting axonal transport [299, 300]. In
various transgenic lines in which human ApoE3 or ApoE4
was expressed under a GFAP or a neuron-speciWc enolase
(NSE) promoter, C-terminal fragments of ApoE4 (and to a
lesser degree of ApoE3) accumulated, and tau protein
appeared to be hyperphosphorylated only in the NSE-ApoE
Tg mice [34].
EVects on synapses
Buttini et al. found in hAPP mice that synaptophysin-
immunoreactive presynaptic terminals, choline acetyltrans-
ferase (ChAT) activity, and ChAT-positive Wbers were
reduced in old apoE-deWcient transgenic mice expressing
human APP. This eVect was prevented by the expression of
the ApoE3 allele [41].
Conclusions
The eVect of ApoE on A metabolism and deposition is
still controversial. The presence of murine or human ApoE
does not directly modify the metabolism of APP, but
increases the number of focal deposits, the number of their
surrounding dystrophic neurites, and the level of vascular
angiopathy. It could also be involved in the transport of A,
since lesions are seen in the thalamus under conditions in
which A is not produced by the thalamic neurons. The
eVects on the phosphorylation of tau are intriguing: they
could provide a link between A and tau alterations;
alternatively, as tau hyperphosphorylation is only foundActa Neuropathol (2008) 115:5–38 25
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when the neuronal expression of ApoE is high, they could
be related to side eVects of the transgenesis. The
importance of ApoE to the trophicity of some synapses
appears to be more Wrmly established, since it is revealed
by knocking out the murine gene. Strangely enough,
whereas ApoE is known to be mainly produced by glia,
most of the eVects are found with a neuronal expression [9],
and this should prompt a re-evaluation of neuronal ApoE in
human pathology.
Modulation of A deposition by other proteins involved in 
cholesterol metabolism: liver X receptor, LRP and ABCA1
Besides the essential role of ApoE in A deposition, a
number of data suggest a link between cholesterol metab-
olism and AD pathology. In APP Tg mice (PSAPP line =
TG2576 £ PS1M146V), dietary cholesterol seems to
accelerate A deposition, whereas cholesterol-lowering
drugs lower it [252, 253]. Inhibition of acyl-coenzyme A
cholesterol acyltransferase (ACAT), an enzyme that con-
trols the equilibrium between free cholesterol and cho-
lesteryl esters, was shown to reduce amyloid pathology
[143].
The liver X receptor (LXR) regulates cholesterol metab-
olism and also plays a role in inXammation: it inhibits the
expression of genes involved in inXammation but promotes
the phagocytosis of A by microglia. Deletion of either
LXR or LXR in APPswe/PS1deltaE9 transgenic mice
resulted in increased amyloid plaque load [349].
LRP is an endocytotic cell-surface receptor that is abun-
dant in neurons (cell body and dendrites). It allows the
internalization of several ligands such as ApoE, APP (with
the Kunitz inhibitor) and 2-macroglobulin. LRP knock-
out mice are not viable. van Uden et al. used mice deWcient
in receptor-associated protein (RAP) to reduce the level of
LRP by 80%. They were crossed with the hAPP line J9.
The amount of amyloid deposits was doubled on the RAP
¡/¡ background, while APP processing was not altered,
suggesting that LRP does indeed help to clear A42 [316].
On the other hand, overexpression of a functional mini
LRP receptor (LRP2) in PDAPP mice produced a decrease
in cerebal ApoE, a moderate but signiWcant increase in
insoluble, detergent soluble (probably membrane-bound)
A42, and a decrease in total A in the CSF. The decrease
in the ApoE level is explained by an accelerated internali-
zation and degradation of ApoE when LRP is overexpres-
sed. The eVect on A42 is abolished in ApoE ¡/¡ mice,
suggesting that it is mediated through the binding of A42
to ApoE. In cell culture, the cells overexpressing
LRP2 clear the A42 present in the culture medium more
rapidly [350].
ABCA1 (ATP-binding cassette transporter A1) is a
major regulator of cholesterol eZux and high-density
lipoprotein (HDL) metabolism. The mutation of ABCA1
in the human causes severe hypercholesterolemia and
marked deWcits of high-density lipoprotein (HDL) and
apoA-I. The level of ApoE is low in the brains of these
patients. In APP23 Tg mice knocked out for ABCA1, the
density of A and Congo red positive deposits is
increased. The amyloid angiopathy is more severe and
associated with microhemorrhages. The level of soluble
ApoE is decreased in the brain [171].
Modulation of A secretion by -synuclein
Lewy and AD pathologies are often associated in the
human and could have a synergistic eVect. On the other
hand, some rare cases of familial Parkinson disease are
linked to mutations on the -synuclein gene. -Synuc-
lein-positive neurites have been mentioned in the aged
TG2576 (APPswe) transgenic line [347]. Such a
pathology in a mouse line without any known alteration
of  -synuclein already hints at cooperation between
amyloid and Lewy pathology. The human wild-type or
mutated (A53T) -synuclein gene has been expressed in
mice under the control of the mouse Thy1 regulatory
sequence [312]. Similar pathological changes were
observed in the two mouse lines. The protein accumu-
lated in the neurons and caused their degeneration.
However, for unknown reasons, the pathology involved
unexpected areas: brainstem neurons and motor neurons
of the spinal cord appeared particularly vulnerable.
There was no expression of the transgenes in the
substantia nigra pars compacta. In other mouse lines in
which the wild-type or the mutated -synuclein gene was
driven by the promoter of the tyrosine-hydroxylase
[210] no degeneration was observed in the substantia
nigra despite a high level of expression. Overexpression
of wild-type and mutated -synuclein in cultures of
dopaminergic neurons, however, caused signiWcant
cell death. Cytoplasmic inclusions were observed
only in the cultures where the mutant gene had been
transfected.
Accumulation of -synuclein occurred earlier in bigenic
mice, hAPP (line J9) £ wild-type -synuclein. Some inclu-
sions appeared Wbrillar in the doubly transgenic animals,
whereas they were always amorphous in the singly trans-
genic animals [206].
In conclusion, the eVects of -synuclein remain contro-
versial: several reports indicate that even the wild-type
form of the human protein may induce pathological
changes. It is however surprising that, in contrast to what is
observed in the human, the dopaminergic system appears
resistant. Although still not well explained, -synuclein and
APP seem to interact in the transgenic lines just as they do
in the human.26 Acta Neuropathol (2008) 115:5–38
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Modulation of the pathology by other proteins
Numerous doubly or triply transgenic lines (only some
listed here) have been generated to elucidate the inXuence
of a candidate protein on the secretion of A peptide or on
the pathology that it generates.
Transthyretin
Transthyretin (TTR) is a serum protein that precipitates in
autosomal dominant familial amyloidotic polyneuropathy,
in familial amyloidotic cardiomyopathy, and in sporadic
senile systemic amyloidosis. It is also said to complex A
peptide that is physiologically present in the CSF of con-
trols and of patients and could prevent amyloid formation
[273]. Mouse strains transgenic for either wild-type or
mutant (TTR L55P) human TTR genes have been produced
and develop TTR deposits in heart and kidney, only some
of which are congophilic. Hemizygous deletion of its gene
favors A deposition in APPswe/PS1deltaE9 mice [58].
Oxidative damage
The homozygous deletion of the superoxide dismutase 2
(SOD2), a mitochondrial enzyme implicated in the protec-
tion against oxidative damage, worsened the cognitive deW-
cit and decreased the microtubule-associated protein 2
(MAP2) immunoreactivity, a sign of dendritic loss. Para-
doxically, it lowered the density of A deposits but
increased amyloid angiopathy [93].
Fyn
Fyn, a tyrosine-kinase that is altered in AD brains, is
located in the postsynaptic density of glutamatergic
neurons. It could be involved in the signal transduction
responsible for the toxic eVect of A on synapses. When
overexpressed in hAPP mice lines J9 and J20, it induced
impaired spatial memory retention and altered emotional
behavior. It also caused changes in the expression of pro-
teins, such as Fos and calbindin [56].
Modulation of the pathology by activity
The eVects of environmental enrichment on A deposition
are contradictory. It was initially found to improve cogni-
tive function but to exacerbate amyloid plaque formation in
APPswe/PS1dE9 mice [150, 151]. In a later study, increas-
ing cognitive, social, or physical activities protected the Tg
mice from the cognitive impairment without aVecting amy-
loid deposition [11]. Physical activity (running wheel: [1])
as well as an enriched environment [5] was found to reduce
A levels in the TgCRND8 line, while another study did
not Wnd any signiWcant eVect on A deposition in the APP-23
mice [339]. In yet another study involving doubly trans-
genic mice TG2576 £ PS1M671L, “complete” environ-
mental enrichment (i.e., in terms of cognitive, social and
physical activities) was shown to signiWcantly reduce the
amyloid load (¡28% in hippocampus and ¡36 in entorhi-
nal cortex). The contradictory results in the literature sug-
gest that the eVects of environmental enrichment and
physical activity are related to additional, badly controlled
factors. Recently, it has been suggested that the ApoE allele
could play a role, since environmental enrichment stimu-
lated apoptosis when the human ApoE4 was expressed on a
murine ApoE deWcient background, while it stimulated
neurogenesis in ApoE3 mice [194].
Trauma
Repetitive mild traumatic injury of the brain increased the
deposition of A peptide in the Tg2576 mouse model.
Single brain trauma had no eVect [308].
Conclusions
The transgenic technology has, for the Wrst time, allowed
the production of some of the lesions observed in human
neurodegenerative diseases. Its success proves, a contrario,
how weak the other methods based on the use of destruc-
tion, toxic agents or observations of naturally occurring ani-
mal diseases were.
We have repeatedly seen in this review that the conclu-
sion that may be drawn from a model depends on the joined
analysis of the transgenic line and of the human disease.
The renewed analysis of the lesions in the animal enlight-
ens our view on the human pathology; ignorance of the
human pathology will undoubtedly lead to erroneous inter-
pretation. This crossed examination implies a double com-
petence—in both human and animal pathology. The
neuropathologist is a key scientist in the exploration of
these new territories.
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